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ABSTRACT 
 Human epidermal growth factor receptor 2 (HER2 or ErBb2) is a receptor 
tyrosine kinase overexpressed in 20-30% of breast cancers and associated with 
poor prognosis and outcome. Dysregulation of several micro RNAs (miRs) plays a 
key role in breast cancer progression and metastasis. In this study, we screened 
and identified miRs dysregulated in HER2-positive breast cancer cells.  Molecular 
study demonstrated that miR-489 was specifically downregulated by the HER2-
downstream signaling, especially the MAPK pathway. Restoration or 
overexpression of miR-489 in HER2-positive breast cancer cells significantly 
inhibited cell growth in vitro and decreased the tumorigenicity and tumor growth in 
xenograft mice.  Mechanistically, we found that overexpression of miR- 489 led to 
the decreased levels of HER2 and thus attenuated HER2-downstream signaling. 
To dissect the role of miR-489 in mammary gland development and HER2 induced 
tumorigenesis, we generated and characterize MMTV-miR-489 mice that 
overexpressed miR-489 in mammary epithelial cells and these mice exhibited an 
inhibition of mammary gland development in early ages with a specific impact on 
highly proliferative cells. Double transgenic MMTV-Her2-miR489 mice were then 
generated to observe how miR-489 overexpression affects Her2 induced 
tumorigenesis. miR-489 overexpression delayed Her2 induced tumor initiation 
significantly. Moreover, miR-489 overexpression inhibited tumor growth and lung 
metastasis. miR-489 overexpression reduced mammary progenitor cell population
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significantly in preneoplastic mammary glands of MMTV-Her2 mice which showed 
a putative transformed population in Her2 induced tumorigenesis. The miR-489 
overexpression reduced CD49fhiCD61hi populations in tumors that have stem- like 
properties, and miR-489 overexpression altered the Her2 signaling pathway in 
mammary tumors. Also, our in vitro data suggest miR-489 restoration can also 
induce significant cytotoxicity in basal breast cancer cells. We also have found low 
amount of miR-489 expression in basal cancer cell lines and basal breast cancer 
patients compare to other subtypes. Our GO pathway analysis from gene 
expression pattern from T47D cells transfected with scr and mimic-miR-489 
suggest genes involved in cell cycle pathway significantly dysregulated upon miR-
489 restoration. We found miR-489 restoration can inhibit CDK1 and FOXM1 in 
breast cancer cells. Overall, our data indicates that miR-489 acts as a tumor 
suppressor miRNA at least partially by targeting HER2 signaling pathway by 
targeting HER2 and SHP2, induce dramatic cell death of basal type of breast 
cancer cell lines by arresting cell cycle in G2/M phase by targeting CDK1 and 
FOXM1 and regulates Her2 targeted progenitor population. Thus, miR-489 
represents a new prognostic biomarker and potential therapeutic agent in breast 
cancer.   
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1.1 BREAST CANCER 
Breast cancer, which consists of cancers originating in the breast tissue that 
are made up of mammary glands for milk production, called lobules, and ducts that 
connect the lobules to the nipple, is second deadliest cancer in the woman after 
lung cancer. According to cancer statistics, approximately 1.7 million new cases 
arise around the globe. According to statistics, ductal carcinoma in situ (DCIS) 
which originates in duct is accounting for 83% which harbor slowly growing tumors 
and lobular carcinoma in situ (LCIS) which originates in the lobules of the breast 
is accounting for 13% which harbor aggressive and invasive tumor. According to 
US breast cancer statistics, 2,66,120 new cases are expected in 2018 in the United 
States (Kubista, 2001).  
Breast cancer is highly heterogenous disease distinguished by up to 21 
distinct histological subtypes and at least four different molecular subtypes which 
are biologically variable in presentation, response to treatment and outcomes. 
Gene expression profiling have pointed out different genetic variability among 
tumors, however due to cost effectiveness it is not used in routine practice. Breast 
cancer has been identified in various classes based on presence or absence of 
several receptor molecules which include the presence or absence of hormone 
2 
(estrogen or progesterone) receptors (HR+/HR-) and excess levels of human 
epidermal growth receptor 2 (HER2+/HER2-), a growth-promoting protein. Among 
this luminal A (HR+/HER2-) is the most abundant (74%) breast cancers express 
the estrogen (ER+) and/ or the progesterone receptor (PR+) but not HER2 (HER2-
). These cancers tend to be slow growing and less aggressive than other subtypes. 
This type of cancer is associated with favorable prognosis because of hormone 
receptors have better response to hormonal therapy. Triple negative (HR-/HER2-
) type consists of about 12% of breast cancer. It is called triple negative because 
of lacking ER, PR and HER2 on their cell receptor. According to statistics, this type 
is two times more common in black women than white women. Also, triple negative 
breast cancers have a poorer short-term prognosis than other breast cancer types 
due to lacking targeted therapies. Luminal B breast cancers are consisting of 
hormone receptor positive and HER2 positive tumor cells. Moreover, this subtype 
also has highly positive Ki67 (indicator of a large proportion of actively dividing 
cells) cells. Luminal B is more aggressive than Luminal A. HER2 enriched (HR-
/HER2+) breast cancers have HER2 over expressing tumor cells. They are mostly 
hormone receptor negative. These cancers tend to grow and spread more 
aggressively than other breast cancers and are associated with poorer short-term 
prognosis compare to ER+ breast cancers. In this study, we have focused on 
HER2 positive and triple negative breast cancer (Kubista, 2001).  
1.2 HER2 SIGNALING PATHWAY 
  Three decades ago, ERBB receptors were linked to human cancer 
pathogenesis. Since than investigators have developed further understanding of 
3 
biology underlying dependence of tumor cell growth on aberrant ERBB receptor 
signaling. The ERBB family is transmembrane receptor tyrosine kinases (RTKs) 
consist of the epidermal growth factor receptor EGFR (ERBB1), HER2 (ERBB2), 
HER3 (ERBB3), and HER4 (ERBB4). EGFR, HER3 and HER4 receptors need 
extracellular ligand binding in order to activate its kinase activity through its 
terminal carboxyl autophosphorylation segment (Rubin & Yarden, 2001). The 
HER1 receptor is activated by epidermal growth factor (EGF), transforming growth 
factor alpha (TGFα), amphiregulin, epigen (EPG), heparin-binding EGF-like growth 
factor, betacellulin and epiregulin. HER3 and HER4 receptors bind neuregulins 
(NGFs). HER2 is a co-receptor for many different ligands and is often activated by 
EGF-like ligands which is resulting in the formation of HER1-HER2 heterodimers. 
Neuregulins can induce the formation of HER2-HER3 and HER2-HER4 
heterodimers. However, till data no ligand has been found which can promote 
HER2 homodimers (Arteaga & Engelman, 2014) (Rubin & Yarden, 2001). 
Although, HER2 doesn’t require any ligand binding but its conformation resembles 
a ligand-activated state and favors dimerization (Matsuoka & Yashiro, 2015). 
HER2 and EGFR activation induces transphosphorylation of the ERBB partner and 
activates intracellular pathway such as RAS/RAF/MEK/ERK, PI3K/AKT/TOR, Src 
kinases and STAT transcription factors(Arteaga, 2011) (Arteaga & Engelman, 
2014). HER3 also can bind ATP and catalyze autophosphorylation, it contains 
weak kinase activity compared to its ERBB counterparts. Since having effective 














key cell proliferation regulatory pathway, ERBB family members have prominent 
role in tumor initiation and maintenance of solid tumor. Because of this reason, 
variety of ERBB inhibitors have been discovered as efficient cancer therapies. 
Moreover, HER2-containing heterodimers generate intracellular signals that are 
significantly stronger than signals emerging from other HER combinations due to 
two reasons: first, the heterodimers are characterized by a relatively slow rate of 
ligand dissociation and second, unlike HER1 whose rate of ligand-induced 
endocytosis is rapid, HER2 is a slowly internalizing receptor. Signaling by HER2-
Figure 1.1: Human epidermal growth receptor 2 signaling pathway. HER1-4 
are transmembrane proteins with tyrosine kinase domain. Hetero or homo 
dimerization result in tyrosine kinase activation with the subsequent signaling 
cascade, and subsequiently activation of downstream signaling including MAPK 
and PI3K/Akt/mTOR pathway. This figure has been adapted from (Matsuoka & 
Yashiro, 2015) 
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containing receptor combinations is relatively prolonged and enhanced activation 
of signaling pathways such as PI3K/AKT and MEK/ERK as demonstrated in figure 
1.1. The HER2 receptor is encoded by the HER2 gene, a proto oncogene mapped 
to chromosome 17q21. The HER2 receptor is a 1255 amino acid, 185 KD 
transmembrane glycoprotein. HER2 plays critical role in cell growth, proliferation, 
survival, and differentiation via its downstream kinase activity (Arteaga & 
Engelman, 2014). However, amplification of the HER2 gene leads to 
overexpression of the receptor which is linked to development of many human 
cancers such as breast, gastric, and esophageal cancer. In breast cancers, 92% 
of cases of HER2 overexpression result from HER2-gene amplification which will 
generate more than two copies. This leads to 100 time increase in synthesis of 
HER2 protein than normal cells. However, mechanism underlying amplification 
has not been elucidated yet (Rubin & Yarden, 2001). In some cases, HER2 
overexpression may result from transcriptional or post-transcriptional 
dysregulation. Mammary promoter regulated overexpression of neu 
protooncogene also demonstrated mammary tumor development in mammary 
gland in long latency. Also, overexpression of HER2 has increased cell motility and 
induction of cellular events associated with tumor progression in normal mammary 
epithelial cells MCF10A. Several clinical analyses also have demonstrated HER2 
positive breast cancer is highly aggressive and has higher risk of recurrence than 




1.3 RESISTANCE TO CURRENT THERAPEUTICS  
Currently, multiple medications have been approved for the treatment of 
HER2 positive breast cancer. Early stage breast cancer is treated with 
Trastuzumab (Herceptin) which is a monoclonal antibody that directly binds to an 
epitope in HER2 receptor and leads to partial inhibition of downstream signaling 
and triggers antibody dependent, cell-mediated cytotoxicity (ADCC). The 
combined treatment of trastuzumab and current chemotherapy demonstrated 
increase survival specially in early stage HER2 positive breast cancer. 
Trastuzumab is also used in later stage cancer patients as well. Pertuzumab 
(Perjeta) is a more recently approved monoclonal antibody which can bind to 
different location of HER2 protein than trastuzumab and inhibit HER2 homodimers 
and HER2-HER3 heterodimers by blocking epitope which results in to partial 
inhibition of PI3K/AKT signaling. Since pertuzumab binds to different epitopes in 
the HER2 ectodomain, pertuzumab and trastuzumab combination has shown 
synergy in preclinical studies and clinical trials. These combinations along with 
standard chemotherapy approved for advance metastatic HER2 positive breast 
cancer. Another drug, ado-trastuzumab emtansine also can be used to treat HRE2 
positive metastatic breast cancer. This drug is also made up of the same 
monoclonal antibody found in trastuzumab attached to the chemotherapy drug 
DM-1. This antibody acts as tumor directed device taking the chemotherapy 
directly to tumor cells. Lapatinib (Tykerb) is ATP-competitive, reversible small-
molecule inhibitor of the HER2 and EGFR tyrosine kinases which quickly disables 
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HER2 signaling. Thus, it significantly inhibits PI3K/AKT and MAPK pathways 
(Arteaga & Engelman, 2014).  
 Although ERBB-targeted therapies have demonstrated substantial benefit 
to patients with advance stage, tumor cells have ultimately have developed both 
de novo and acquired resistance to the current approaches. Here term de novo 
means intrinsic resistance which refers to tumor cells that do not exhibit an initial 
response and acquired means resistance developed after an initial durable clinical 
response.  Some resistance mechanisms affect the capacity for HER2 inhibitors 
to directly engage HER2 (Kurokawa & Arteaga, 2003). A truncated form of HER2 
p95-HER2 is lacking trastuzumab binding region. This initiate due to alternate 
transcription start sites in HER2. Also, it has been shown patients with metastatic 
breast cancer having cytosolic expression of p95-HER2 exhibit a very low 
response to trastuzumab compared to patients without p95-HER2 in their tumors. 
There is another splice variant which eliminates exon 16 in the extra cellular 
domain of the HER2 receptor which is known as Δ16 HER2 isoform. This isoform 
doesn’t eliminate trastuzumab epitope on HER2 but stabilizes HER2 homodimers 
and prevents their disruption upon binding by the antibody which results in 
trastuzumab resistant tumor cells. Also, HER2 mutations have been found in a 
small proportion of lung, gastric, colorectal, breast, head and neck cancers and 
these mutants are resistant to lapatinib and trastuzumab. Here are some examples 
of common mutation in HER2 in breast cancer patient: 2263-2278del, 2264T to C 
and 2264 T to C in exon 19 and 2686 C to T in exon 22(J. W. Lee et al., 2006). 
Although, these mutations have not been found in HER2 amplified genes but very 
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small portion of the amplified HER2 alleles have these mutations. There is one 
possibility that cancer cells harboring these mutations will be selected or acquired 
after the selective pressure of anti-HER2 treatments. In this case, those tumors 
will be only detected after escaping from primary HER2-targeted therapy. Also, 
most of these drugs inhibit downstream signaling specifically PI3K/AKT and 
MEK/ERK, many cancers are resistant to single agent ERBB inhibitors because at 
least one of these critical downstream pathways is maintained despite inhibition of 
the targeted receptor. This type of resistance is termed as by pass track resistance. 
Also, some clinical studies have pointed out presence of somatic mutation in 
EGFR, K-RAS, PIK3CA and BRAF genes in the carcinoma samples with above 
mentioned ERBB mutations (Figure 1.2). Cancer patients harboring these 
mutations showed resistant to HER2 targeted therapies. One study has pointed 
out HER2 amplification and phosphatidylinositol-4,5-bisphosphoate 3-kinase 
(PI3K) mutation (PIK3CAH1047R) co-occur together and promotes HER2-mediated 
breast epithelial transformation and metastatic progression. Patients with this 
mutation have demonstrated resistance to anti-HER2 therapies(Hanker et al., 
2013). Reactivation of EGFR and HER3 can serve as a mechanism of resistance 
to ERBB inhibitors. In one study, it has been demonstrated HER2 amplified breast 
cancer treated with trastuzumab showed increased levels of EGFR and ERBB 
ligands led to an increase in active EGFR/HER3 and EGFR/HER2 dimers to 
promote resistance(Ritter et al., 2007). Also, IGF-1 receptor overexpression has 
increased levels of IGF-1R/HER2 heterodimers which can reactivate PI3K/AKT 
signaling and confer resistant to trastuzumab treatment(Huang et al., 2010). 
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Studies have also suggested defects in apoptosis and cell cycle related proteins 
also increase resistance to HER2 targeted therapy(Chakrabarty et al., 2010; Xia 
et al., 2006). Also, mesenchymal to epithelial transition activation by either gene 
amplification or ligand stimulation also can cause bypass resistance to EGFR and 
HER2 inhibitors. Thus, it is necessary to identify prognostic factor which can 





Figure 1.2: Resistant to HER2 targeted therapy. A. Model of a sensitive HER2-
addicated cancer treated with an ERBB small-molecule inhibitors or antibody 
resulting in suppression of downstream signaling. B. Model of HER2 amplified cancer 
with resistance due to maintenance of downstream signaling in the presence of the 
HER2 inhibitors. This figure has been adapted from (Arteaga & Engelman, 2014) 
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1.4 MIRNA 
miRNAs are short 18-24 nucleotide long single stranded highly conserved 
non-coding RNA molecules synthesized from precursor hairpin shaped double-
stranded RNAs that fine-tune gene expression in multitude of physiological and 
pathological process. miRNAs regulate protein synthesis in the cell cytoplasm by 
promoting target mRNAs degradation and/or inhibiting their translation by binding 
to 3’-UTR of mRNA in sequence dependent manner. Since each miRNA can target 
hundreds of genes, they can play pivotal role in highly regulated cellular processes 
such as proliferation, differentiation and survival(Mukherji et al., 2011; 
Ramalingam et al., 2014).  
Biosynthesis of miRNAs is a complicated process. The majority of miRNAs 
are transcribed through RNA Pol II into primary miRNA (pri-miRNA) with long stem 
loop structure. These pri-miRNAs are cleaved in to approximately 70-80 nucleotide 
long precursor microRNA (pre-miRNA) by RNAse III endonuclease Drosha. These 
pre-miRNAs are transported by mainly exportin-5. The pre-miRNAs are cleaved 
into mature 18-24 nucleotide long miRNA by RNAse III type enzyme Dicer. Dicer 
is highly specific enzyme which forms complex with two other proteins TRBP and 
PACT to form miRNA induced silencing (RISC) complex. RISC complex directly 
involve in RNA silencing process in which miRNA functions as a guide by base 
pairing with its target mRNAs, whereas AGO proteins function as effectors by 
recruiting factors that induce translational repression, mRNA deadenylation and 
mRNA decay. miRNA binding sites are usually located in 3’ untranslated region 
(UTR) of mRNAs. The 5’ end of miRNAs that spans from nucleotide position 2 to 
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7 is critical for target recognition and has been given term ‘miRNA seed’. miRNAs 
are very crucial molecules since each miRNA targets hundreds of genes and 
majority of protein coding genes are miRNA targets. Thus, their expression is 
tightly regulated and their dysregulation is often associated with various human 
disease including cancer and neurodevelopmental disorders(Bartel, 2004; H. Y. 
Lee & Doudna, 2012; Y. Lee et al., 2003; Shah & Chen, 2014).  
miRNA regulation takes place at multiple steps which include their 
transcription, their processing by Drosha and Dicer, their loading onto AGO 
proteins and miRNA turn over. Based on their genomic location, miRNAs are 
generally classified as intergenic or intronic. Intergenic miRNAs are located in 
previously identified unannotated regions of the human genome and are 
transcribed from their own promoter as long primary transcripts. Intronic miRNAs 
are located in introns of the gene and in majority case they share promoter with 
their respective host gene. miRNA biogenesis has been demonstrated in figure 
1.3. 
1.5 ROLE OF MIRNA IN CANCER PROGRESSION 
Role of miRNA dysregulation in breast cancer was first demonstrated in 2005. 
Since then many studies have indicated their extensive role in breast cancer 
initiation, progression and metastasis (Figure 1.4).  miR-7 family, miR-125, miR-
205, miR-200 family, miR-206, miR-34a, miR-335, miR-342, miR-15a/16, miR-
302, miR-31, miR-519c etc. have been found as tumor suppressor miRNAs in 
breast cancer. miRNAs promote tumorigenesis by targeting tumor suppressor 
12 
mRNAs in different human cancers(Feliciano et al., 2013; Scott et al., 2007; 



















Figure 1.3: General mechanism of miRNA biogenesis. The canonical 
maturation includedes the production of the primary miRNA transcript (pri-miRNA) 
by RNA polymerase II or III and cleavage of the pri-miRNA transcript (pri-miRNA) 
by Drosha-DGCR8 in the nucleus. The resulting pre-miRNA is exported by 
Exportin5-RAN-GTP. In the cytoplasm, the RNase Dicer in complex with the 
double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to 
mature length. The functional strand of the mature miRNA is loaded together with 
Argounaute (Ago2) proteins into the RNA-induced silencing complex (RISC) where 
it guides RISC to silence its target mRNAs through mRAN cleavage, translational 
repression or deadenylation. This figure has been adapted from (Winter, Jung, 
Keller, Gregory, & Diederichs, 2009) 
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The miRNAs which enhance tumorigenesis and/or metastasis are classified as 
oncogenic miRNAs. Several miRNAs such as miR-10b, miR-126, miR-155, miR-
21, miR-375, miR-221/222, miR-373, miR-520c, miR-9, miR-7, miR-203 etc. have 
been identified as oncogenic miRNAs in breast cancer since their role have been 
found in promoting tumorigenesis by inducing cell proliferation, metastasis and 
angiogenesis(Gabriely, Teplyuk, & Krichevsky, 2011; Png, Halberg, Yoshida, & 
Tavazoie, 2011; Shah & Chen, 2014). Out of these some of the miRNAs have been 
found to promote metastasis in breast cancer and they are referred as 
MetastamiRs(Hildebrandt et al., 2010; Khew-Goodall & Goodall, 2010). miR-520c 
and miR-373 have been demonstrated to enhance migration and invasion both in 
vitro and in vivo by targeting the expression of CD44(K. Yang, Handorean, & 
Iczkowski, 2009). miR-9 also has been demonstrated significantly upregulated in 
breast cancer by targeting E-cadherin(Shah & Chen, 2014).  
Dysregulation of miRNAs also have been linked to various resistant 
mechanisms developed by cancer cells against traditional therapies. Studies have 
reported miR-7, miR-27, miR-326, miR-328, miR-451, miR-489 expressions link to 
confer resistant to chemotherapeutic drugs such as doxorubicin, cisplatin or 
taxol(Chekhun, Lukyanova, Kovalchuk, Tryndyak, & Pogribny, 2007; Kovalchuk et 
al., 2008; Shah & Chen, 2014; M. Zhou et al., 2010). These miRNAs have been 
shown either targeting proteins involve in drug metabolisms and ABC transporters 
which affect drug availability in the cell. Dysregulation of tumor suppressor miRNAs 
miR-342 and miR-15a/16 are related to the tamoxifen resistance in HER2 
overexpressing breast cancer. Study has shown decreased levels of miR-342 and 
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miR-15/16 expression has contributed to tamoxifen resistance by increasing anti-
apoptotic protein B-cell lymphoma 2 (BCL2) in HER2Δ16 overexpressing 
cells(Cittelly et al., 2010). Similarly, expression of miR-34a is also found to be 
downregulated in breast cancer. It is reported miR-34a is regulated by p53. Triple 
negative breast cancer cell line MDA-MB-231 with low amount of miR-34a was 
more resistant to radiation therapy compared with elevated level of miR-34a. Also, 
it was reported miR-34a inhibits cell proliferation and cell migration by directly 
inhibiting BCL2 and sirtuin(L. Li et al., 2013). Several chemotherapeutic drugs 
used as first line treatment in breast cancer intervene with cellular functions such 
as DNA repair, cell cycle, and apoptosis. Over expression of proteins involved in 
DNA repair pathway are linked with resistance to chemotherapeutic drugs. miR-21 
and miR-141 are associated with drug resistance due to targeting key proteins 
involve in mismatch repair pathway(Bandres et al., 2006; Valeri et al., 2010). The 
down regulation of miR-125 and miR-331 is found to be responsible for reduced 
efficacy of HER2 targeted therapy such as trastuzumab(Kovalchuk et al., 2008). 
Also, both miR-125 and miR-331 can inhibit HER2(Shah & Chen, 2014). Since 
miRNAs acting as tumor suppressors or oncogenes (oncomiRs), miRNA mimics 
and molecules target endogenous miRNA (antimiRs) have shown promise in 
preclinical development. Several miRNA-targeted therapeutics have reached 
clinical development, including miR-34 mimic which is tumor suppressor miRNA is 
in phase-I clinical trial for treating cancer and antimiR-122 which is oncogenic miR 
is in phase-II for treating hepatitis(Rupaimoole & Slack, 2017). Thus, having 
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potential to target multiple genes involve in different key pathways, miRNA holds 
promising potential therapeutic to combat cancer efficiently.  
We hypothesized HER2 overexpression may dysregulate miRNA 
expression and its targets which might play role in HER2 mediated tumorigenesis 




1.6 GOALS OF THE PROJECT 
The overall goal of this project is to understand the role of dysregulated 
miRNAs in the HER2 overexpressing breast cancer. Since having multiple 
resistant mechanisms to traditional HER2 targeted therapies, we want to find out 
Figure 1.4: Demonstration of role of miRNA in cancer. microRNA regulation of 
apoptosis, tumorigenesis, and angiogenesis in breast cancer. miRANs listed in the 
left column act to repress pro-cancer phenotypes by direct targeting of oncogenic 
mRNAs. miRNAs in the right column target mRANs coding for genes with known 
tumor suppressive functions and thus promote the development of cancer traits by 
cells. This figure has been adapted from (Alahari, Eastlack, & Alahari, 2016) 
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new candidate miRNA which can inhibit multiple oncogenic pathway and act as 
potential adjuvant along with traditional HER2 targeted therapies to avert resistant 
to traditional therapy. 
We started our study with screening with miRNAs expression between 
MCF7 Vector and HER2 cells. By using HER2 signaling inhibitors, we found 
selected miRNAs whose expression can be changed upon blocking HER2. We 
specifically found miR-489, whose expression is down regulated upon HER2 
overexpression and its expression can be rescued upon HER2 signaling inhibition. 
In this study, we have focused on finding role of miR-489 in HER2 positive breast 
cancer and how miR-489 can act as tumor suppressor miRNA in HER2 positive 
breast cancer. By using breast cancer cell lines and patient samples and data 
base, we tried to find out whether miR-489 is bona fide tumor suppressor miRNA. 
Also, we want to find out miR-489 gene targets and due to these targets, which 
are the oncogenic pathways inhibited by miR-489.  
miR-489 has been demonstrated as switch between active stage of stem 
cells and quiescent stage of stem cells in muscle system. In this study, they 
reported miR-489 expression is crucial to maintain quiescent stage of stem 
cells(Cheung et al., 2012). We further want to explore whether miR-489 has any 
similar role in mammary gland system. To address this question, MMTV-miR-489 
mouse model will be established which specifically overexpress miR-489 in 
mammary epithelial cells. By using this mouse model, we want to find whether 
miR-489 has any role in mammary gland development. MMTV-Her2 mouse model 
has been established previously to study detail mechanisms underlying Her2 
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mediated tumorigenesis in mouse(Guy et al., 1992). This mouse model mimic 
human HER2 positive breast cancer. These mice also spontaneously demonstrate 
mammary tumor. Previously, we demonstrated altered progenitor cells are 
responsible for Her2 induced tumorigenesis in MMTV-Her2 mouse model(Lo et al., 
2012). We want to explore whether miR-489 play role in stem-progenitor axis 
which is regulating progenitor cell population. By using this mouse model, we want 
to further expand our study and find role of miR-489 in Her2 mediated tumor 










A NOVEL DOUBLE-NEGATIVE FEEDBACK LOOP BETWEEN 
MIR-489 AND HER2-SHP2-MAPK SIGNALING AXIS REGULATES 
BREAST CANCER CELL PROLIFERATION AND TUMOR GROWTH 
2.1 INTRODUCTION 
Breast cancer is a heterogeneous disease with several subtypes identified 
by unique molecular signatures(Heiser et al., 2012; Higgins & Baselga, 2011; Shah 
& Chen, 2014). Nearly, 30% of total breast cancer patients overexpress human 
epidermal growth factor receptor 2 (ErbB2 or HER2)(Cittelly et al., 2010; Corsini 
et al., 2012; Gajria & Chandarlapaty, 2011; Zhu & Verma, 2015). It is well 
documented in the literature that overexpression of HER2 promotes aggressive 
tumor phenotype, increases metastasis and decreases overall survival of 
patients(Indira Chandran, Eppenberger-Castori, Venkatesh, Vine, & Ranson, 
2015; Shah & Chen, 2014; Zhu & Verma, 2015). Trastuzumab, a monoclonal 
antibody to HER2, accrues significant clinical benefit in the metastatic and adjuvant 
settings. However, some patients suffer disease recurrence despite adjuvant 
trastuzumab therapy, and many patients with metastatic disease do not respond 
to therapy or develop refractory disease within 1 year of treatment(Cittelly et al., 
2010; Gajria & Chandarlapaty, 2011).  Thus, identification of specific molecular 
factors, which can regulate HER2 signaling is critical for more targeted and efficient 
therapy against HER2 positive breast cancer. 
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The microRNAs are small (18-25 nucleotide) long non-coding, single stranded 
RNAs, which regulate the expression of various genes at post-transcriptional level 
mostly by binding to the partially complementary site on 3’UTR region of target 
mRNA (Qian et al., 2009; Shah & Chen, 2014; J. Zhou et al., 2013). It has also 
been implicated that HER2 regulates the expression of specific miRNAs to 
promote cell proliferation and tumorigenesis. In a micro array study, Mattie et al. 
found that several miRNAs are found to be down-regulated in HER2 positive 
tumors compare to the HER2 negative tumors. Down-regulation of miR-205 by 
HER2 is shown to enhance tumorigenesis in breast cancer. (Adachi et al., 2011). 
A recent study has found that hyper-methylation of miR-200b promoter is 
associated with higher HER2 expression(Wee et al., 2012). Moreover, aberrant 
expression of specific miRNAs by HER2 leads to the enhanced resistance to 
chemotherapeutic drugs(Ichikawa et al., 2012; Iorio et al., 2009; Talotta et al., 
2009; S. E. Wang & Lin, 2013). However, it still remains largely unknown how 
HER2 promotes tumor progression via regulation of specific microRNAs.   
A few recent studies have shown that miR-489 plays an important role in 
both development and tumorigenesis. Cheung et al. has shown that the miR-489 
pathway is essential for the maintenance of the quiescent state of muscle stem 
cells(Cheung et al., 2012). In addition, miR-489 seems to play a tumor suppressive 
role in a few different types of cancers. The expression of miR-489 is 
downregulated in hypopharyngeal squamous cell carcinoma (HSCC), non-small 
cell lung cancer (NSCLC) and in breast cancer(Jiang et al., 2014; Kikkawa et al., 
2010).  Overexpression of miR-489 inhibited cell growth and invasion, epithelial-
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to-mesenchymal transition (EMT) properties by targeting several genes including 
Shp2, Smad3, Akt3 and Suz12. In addition, loss of miR-489 expression confer 
tumor cells resistance to chemotherapeutic drugs(Pogribny et al., 2010). Overall, 
these data suggest that dysregulation of miR-489 may contribute to tumor 
development and affect the sensitivity to anti-cancer drugs by regulating different 
target genes in a context-dependent manner.  
In this study, we identified miR-489 as one of the candidate miRNA whose 
expression was downregulated by HER2 downstream MAPK signaling and for the 
first time showed that miR-489 directly binds to the 3’-UTR of HER2 mRNA and 
down-regulates its expression. We also confirmed that miR-489 can target another 
HER2 downstream gene Shp2 in breast cancer cells. Therefore, the HER2-SHP2-
MAPK and miR-489 signaling pathways form a double negative feedback loop 
which regulate breast cancer cell proliferation both in vitro and in vivo. Moreover, 
our clinical data analysis indicated that miR-489 expression was significantly 
downregulated in tumor tissues compared to the normal breast tissues from same 
patients. The close association of miR-489 expression with clinical parameters 
implicate that miR-489 can be a new prognostic marker and a potential therapeutic 








2.2 RESULTS  
2.2.1 DEMONSTRATION OF QRT-PCR ANALYSIS OF 340 MIRNAS BETWEEN 
MCF7 VECTOR AND HER2 ISOGENIC CELL LINES. 
Our goal was to identify HER2 dysregulated miRNAs in breast cancer. To 
identify specific miRNAs that may be involved in promotion of breast cancer 
progression, we screened expression profiles of several (~300) miRNA between 
HER2 over-expressing and control MCF7 cells using quantitative RT-PCR (qRT-
PCR) analysis (Table 2.1). We found that 21 of dysregulated miRNAs were 
significantly upregulated, whereas 19 were down regulated in MCF7 HER2 cells 
compared to the MCF7 Vect cells as shown in Figure 2.1. Many of these 
upregulated miRs were known oncomiRs in breast cancer, such as miR-200, miR-
141 and miR-223 (Finlay-Schultz et al., 2014; Le et al., 2014; Pinatel et al., 2014), 
Also, many of down-regulated miRs in MCF7 HER2 cells were tumor suppressors, 
such as miR-125b, miR-31 and miR-99a (Feliciano et al., 2013; Hu, Zhu, & Tang, 
2014; Mulrane, Gallagher, & O'Connor, 2014). Also, we found some of the miRNAs 
were previously reported as onco-miR as well. miR-10a and miR-10b were 
significantly down regulated upon HER2 overexpression. Overall, these results 
indicate aberrant miRNA expression pattern between MCF7 Vector and HER2 
cells may be due to HER2 overexpression. It is important to find how these 







































Figure 2.1: Screening of miRNAs differentially expressed in MCF7 
Vector and HER2 cells. Out of total ~200 miRNA screened for 
differential expression between MCF-7 vect and MCF-7 HER2 cells, ~40 
miRs showed significant difference in their expression as shown in the 
schematic heat-map representation. Expression levels of each miRNA 
was quantified by qRT-PCR analysis from three independent 
experiments. Heatmap colors are indicative of miRNA expression as 




Table 2.1 Expression analysis of different miRNAs in MCF7 HER2 cells 





    
Experiment 
#2 




  Vect ΔCt 
HER2 
ΔCt 
ΔΔCt Vect  ΔCt 
HER2 
ΔCt 
ΔΔCt     
135b-
5P 
14.47 9.48 4.99 17.14 13.02 4.12 24.6 10.15 
184 15.51 11.49 4.02 15.92 12.85 3.07 12.3 5.54 
10a-5P 10.4 7.51 2.89 15.35 11.64 3.71 10.23 4.01 
219-5p 15.11 11.96 3.15 15.83 13.48 2.35 6.99 2.7 
32-5p 9.97 7.17 2.8 10.36 9.49 0.87 4.4 3.65 
Let 7a-
5P 
7.7 6.67 1.03 10.14 7.49 2.65 4.16 3.01 
329 16.37 13.73 2.64 13.15 13.81 -0.66 3.43 3.95 
33b-5p 7.41 5.98 1.43 8.95 6.91 2.04 3.4 1 
let 7g-
5P 
7.57 6.63 0.95 8.78 6.95 1.83 2.74 1.15 
200b-
3p 
4.71 3.67 1.04 11.88 10.22 1.66 2.61 0.78 
449a 12.65 11.89 0.76 13.24 11.49 1.75 2.53 1.19 
365a-
3p 
9.02 8.66 0.35 10.31 8.43 1.87 2.47 1.69 
200a-
3p 
4.77 4.07 0.71 7.38 5.75 1.63 2.37 1.04 
29c-3p 5.5 4.72 0.77 6.92 5.37 1.54 2.31 0.85 
141-3p 2.63 2.33 0.3 7.01 5.34 1.68 2.22 1.39 
let 7e-
5P 
4.71 4.34 0.38 8.27 6.64 1.63 2.19 1.26 
320c 7.35 6.24 1.11 10.53 9.4 1.13 2.17 0.02 
21-5p -3.12 -4.06 0.94 -0.78 -1.96 1.19 2.1 0.25 
7-5p 5.71 5.3 0.41 10.21 8.73 1.47 2.05 1.03 
30e-5p 9.41 8.17 1.24 11.03 10.32 0.72 2.01 0.51 
223 10.93 10.91 0.02 14.54 13.02 1.51 1.94 1.3 
425-5p 1.91 1.77 0.13 6.71 5.32 1.39 1.86 1.08 
222-3p 6.16 5.36 0.8 6.41 5.45 0.97 1.85 0.15 
9-5p 11.7 12.55 -0.85 14.92 13.29 1.63 1.82 1.79 
221-3p 4.55 4.16 0.39 4.4 3.18 1.22 1.82 0.72 
539-5p 15.41 15.65 -0.24 19.56 18.08 1.47 1.81 1.37 
208b 14.82 13.17 1.65 15.22 16.39 -1.17 1.79 1.9 
139-5P 7.25 6.54 0.71 7.69 6.98 0.72 1.64 0.01 
320b 1.71 1.02 0.69 1.78 1.12 0.66 1.6 0.02 




1.6 0.98 0.62 2.6 1.9 0.69 1.58 0.06 
29a-3p 4.87 4.85 0.02 5.13 4.05 1.08 1.56 0.78 
378a-
3p 
3.16 2.78 0.38 3.3 2.47 0.83 1.54 0.34 
193a-
5p 
3.46 3.48 -0.01 4.71 3.65 1.07 1.54 0.78 
369-5p 14.51 13.37 1.14 19.54 19.76 -0.22 1.53 0.96 
25-3p -1.52 -1.74 0.22 -0.78 -1.7 0.92 1.53 0.52 
215 7.68 7.66 0.02 9.53 8.51 1.03 1.52 0.72 
141 2.34 2.43 -0.09 4.72 3.68 1.05 1.5 0.79 
33a-5p 2.95 2.29 0.65 3.23 2.8 0.43 1.46 0.16 
26a-5p 1.3 1.46 -0.16 4.27 3.27 1.01 1.45 0.79 
30b-5p 2.45 1.79 0.66 3.51 3.13 0.38 1.44 0.2 
320a -1.09 -1.66 0.56 -0.73 -1.21 0.48 1.44 0.06 
296-5p 1.83 1.59 0.23 1.83 1.07 0.76 1.44 0.37 
218-5p 11.75 10.86 0.89 13.38 13.43 -0.05 1.41 0.63 
362-5p 8.01 7.15 0.86 7.49 7.56 -0.07 1.38 0.61 
455-5p 7.19 6.82 0.38 7.2 6.68 0.52 1.37 0.1 
22-3p 2.24 2.04 0.21 1.93 1.3 0.63 1.35 0.28 
30a-5p 7.8 7.24 0.56 9.48 9.19 0.29 1.35 0.18 
429 5.11 4.72 0.39 8.08 7.63 0.45 1.34 0.04 
200c-
3p 
-2.09 -2 -0.09 -0.31 -1.1 0.79 1.34 0.56 
365b-
3p 
7.64 8.8 -1.16 9.41 8.26 1.14 1.33 1.25 
30c-5p 3.16 2.55 0.61 3.82 3.68 0.14 1.31 0.3 
194-5p 3.22 3.19 0.03 4.01 3.35 0.65 1.3 0.39 
95 8.17 8.9 -0.73 14.22 13.23 0.99 1.3 0.98 
338-5p 6.54 6.13 0.4 7.92 7.61 0.31 1.28 0.06 
501-5p 9.77 9.34 0.42 9.79 9.55 0.24 1.26 0.12 
205 5.97 6.21 -0.23 7.6 6.88 0.73 1.25 0.57 
let 7c 6.67 6.8 -0.13 10.36 9.69 0.66 1.25 0.48 
19a-3p 0.36 0.81 -0.45 2.55 1.73 0.81 1.25 0.73 
504 8.2 8.31 -0.1 10.37 9.8 0.56 1.2 0.39 
301c-
3p 
0.46 0.61 -0.15 2.1 1.56 0.53 1.17 0.39 
34a-5p 0.71 0.44 0.27 0.4 0.21 0.18 1.17 0.05 
199a-
3p 
11.48 11.68 -0.2 12.67 12.12 0.55 1.17 0.42 
193b-
3p 
-0.73 -0.52 -0.2 -0.54 -1.07 0.53 1.16 0.41 
30d-5p 3.27 3.14 0.13 4.74 4.46 0.28 1.15 0.08 
93-5p -1.1 -1.21 0.11 -0.73 -1.01 0.28 1.15 0.09 
103a-
3P 
-1.07 -1.31 0.24 -0.83 -0.96 0.13 1.14 0.06 
25 
212 5.41 5.78 -0.37 6.53 5.95 0.58 1.14 0.51 
150-5p 12.02 11.63 0.39 12.07 12.16 -0.09 1.13 0.26 
let 7i -
5P 
2.49 2.21 0.28 3.19 3.14 0.05 1.12 0.13 
361-5p 8.74 8.74 -0.01 13.84 13.52 0.31 1.12 0.18 
302c-
3p 
17.62 19.16 -1.54 18.67 17.76 0.91 1.11 1.09 
let 7d-
5P 
2.24 2.27 -0.03 3.96 3.67 0.29 1.1 0.17 
181b-
5p 
4.7 4.25 0.45 4.56 4.94 -0.38 1.07 0.42 
192-5p 3.43 3.07 0.36 4.44 4.67 -0.24 1.07 0.31 
126-3P 1.84 1.59 0.25 2.7 2.81 -0.11 1.06 0.18 
146a-
5P 
9.9 11.12 -1.21 14.01 13.27 0.74 1.05 0.88 
205-5p 4.6 5.02 -0.43 5.08 4.66 0.42 1.04 0.42 
422a 5.73 6.23 -0.5 6.6 6.15 0.46 1.04 0.47 
181d 5.51 5.22 0.3 5.73 6 -0.27 1.03 0.28 
500a-
5p 
7.69 7.79 -0.1 8.71 8.54 0.17 1.03 0.13 
23a-3p -2.29 -1.81 -0.48 -1.15 -1.55 0.4 1.02 0.43 
326 4.3 4.73 -0.44 4.5 4.13 0.37 1.02 0.39 
125a-
5P 
-1.45 -1.4 -0.04 -0.08 -0.14 0.05 1 0.05 
193a-
5p 
3.73 4.16 -0.44 4.58 4.27 0.31 0.99 0.35 
199b-
5p 
7.44 7.86 -0.43 9.13 8.83 0.3 0.99 0.35 
191-5p -0.56 -0.67 0.11 0.39 0.58 -0.19 0.98 0.14 
485-5p 12.21 12.77 -0.56 13.37 13.04 0.33 0.97 0.41 
500b 15.74 15.37 0.37 17.44 18.1 -0.66 0.96 0.47 
523-3p 13.56 14.15 -0.59 13.18 12.85 0.33 0.96 0.42 
96-5p 2.58 2.97 -0.39 3.65 3.48 0.17 0.94 0.26 
20b-5p 6.38 6.67 -0.3 6.82 6.72 0.1 0.94 0.18 
196b-
5p 
6.73 7.56 -0.83 8.32 7.93 0.4 0.94 0.53 
99b-5p -1.14 -0.79 -0.35 -0.81 -0.92 0.11 0.93 0.21 
495-3p 12.93 12.31 0.62 12.36 14.06 -1.7 0.92 0.87 
301b 4.44 4.65 -0.2 5.22 5.26 -0.04 0.92 0.08 
19b-3p -0.58 -0.08 -0.51 0.34 0.16 0.19 0.92 0.31 
339-5p -0.66 -0.66 0 -0.51 -0.24 -0.27 0.91 0.12 
155-5p 17.08 16.52 0.56 19.26 20.94 -1.68 0.9 0.82 
146b-
5p 
5.77 5.75 0.02 7.09 7.47 -0.38 0.89 0.18 
148a-
3p 
3.5 3.41 0.09 3.82 4.43 -0.61 0.86 0.29 




0.17 0.32 -0.15 0.42 0.74 -0.33 0.85 0.07 
132-3P 4.14 4.35 -0.21 4.91 5.2 -0.29 0.84 0.03 
299-5p 12.57 15.86 -3.29 15.97 15.31 0.66 0.84 1.05 
34c-3p 11.76 11.37 0.4 13.26 14.72 -1.46 0.84 0.67 
130b-
3P 
5.56 5.96 -0.4 5.69 5.84 -0.15 0.83 0.1 
Let 7b-
5P 
2.68 2.88 -0.2 2.74 3.1 -0.35 0.83 0.06 
18b-5p 7.18 8.34 -1.16 10.6 10.36 0.24 0.82 0.52 
212-3p 8.69 8.92 -0.23 13.45 13.84 -0.39 0.81 0.06 
140-5P 7.6 7.52 0.07 9.37 10.23 -0.87 0.8 0.36 
152 2.73 2.94 -0.21 3.48 3.94 -0.45 0.8 0.09 
505-3p 3.77 3.99 -0.22 4.41 4.85 -0.44 0.8 0.09 
526b-
5p 
14.09 14.55 -0.46 18.04 18.25 -0.21 0.8 0.1 
153 15.92 15.87 0.04 16.56 17.43 -0.87 0.79 0.34 
335-5p 9.72 9.65 0.07 13.06 13.99 -0.93 0.79 0.37 
16-5p -3.58 -3.43 -0.15 -2.9 -2.32 -0.59 0.78 0.17 
15a-5p 0.58 0.62 -0.04 0.63 1.39 -0.76 0.78 0.27 
148b-
3p 
2.98 3.34 -0.37 3.32 3.66 -0.34 0.78 0.01 
24-3p -0.71 0.05 -0.76 -0.21 -0.15 -0.05 0.78 0.26 
23b-3p -0.66 -0.15 -0.51 -0.24 0.05 -0.29 0.76 0.08 
377-3p 11.39 12.92 -1.53 13.73 13.51 0.23 0.76 0.58 
331-5p 9.17 9.1 0.08 8.66 9.83 -1.17 0.75 0.43 
20a-5p 1.51 2.01 -0.5 2.07 2.42 -0.35 0.75 0.05 
149-5p 1.64 2.13 -0.48 2.83 3.23 -0.4 0.74 0.03 














Table 2.2 Expression of dysregulated miRNAs in MCF7 Vector and HER2 
cell treated upon lapatinib  
miRNA Vec Vec Lapatinib HER2 
HER2 
Lapatinib 
99a-5p 1 1.22 0.02 0.02 
125b-5p 1 1.08 0.01 0.02 
489 1 1.15 0.11 0.21 
375 1 1.00 1.89 1.97 
195-5p 1 1.26 0.33 0.45 
10a-5p 1 1.49 14.32 12.72 
372 1 3.52 3.85 1.90 
299-5p 1 1.25 0.46 0.53 
101-3p 1 0.21 0.11 0.06 
382-5p 1 0.56 0.29 0.21 
135b-5p 1 0.58 3.49 27.38 
487b 1 1.53 0.48 0.36 
485-3p 1 1.12 1.85 0.13 
31-5p 1 0.91 0.03 0.03 
483-5p 1 1.09 0.99 0.88 
450a-5p 1 0.31 0.15 0.08 
203a 1 1.66 1.21 1.27 
let 7a-5p 1 1.16 3.98 9.55 
101-3p 1 3.86 0.61 2.46 
103b 1 1.67 0.51 0.65 
105-5p 1 1.20 2.09 3.36 
122-5p 1 7.61 8.29 10.96 
146a-5p 1 1.80 1.54 1.67 
18a-5p 1 1.00 0.69 0.69 
18b-5p 1 1.19 0.77 1.05 
208b 1 2.43 2.34 3.98 
219-5p 1 0.93 1.09 1.93 
299-5p 1 1.90 3.55 1.91 
30e-5p 1 0.92 1.14 1.01 
31-5p 1 0.80 0.04 0.03 
320c 1 0.95 0.99 1.01 
496 1 0.22 0.19 0.36 
506-3p 1 7.08 5.40 2.89 
507 1 3.42 0.72 1.36 
515-5p 1 1.29 0.66 0.44 
517a-3p 1 1.20 0.78 2.47 
28 
517c-3p 1 5.28 1.83 2.61 
518a-5p 1 2.22 13.93 1.11 
519a-3p 1 6.55 4.90 4.00 
184 1 0.75 4.05 5.27 
 
2.2.2 IDENTIFICATION OF HER2-REGULATED MIRNAS IN BREAST CANCER 
CELL 
To determine specific miRNAs truly driven by HER2 signaling, we blocked 
the HER2 kinase activity by treating MCF7 vect and MCF7 HER2 cells with 
EGFR/HER2 dual inhibitor lapatinib for 48 h. Lapatinib treatment as expected, 
resulted in the almost complete blockade of HER2, AKT and Mitogen activated 
protein kinase (MAPK) phosphorylation as shown in figure 2.2 A, a readout of 
lapatinib inhibition of HER2 signaling. We then performed the qRT-PCR using the 
RNA from lapatinib treated vector and HER2 cells to identify miRs which restore 
their expression by inhibition of HER2 signaling (Table 2.2). Our qRT-PCR data 
demonstrated that miR-489, miR-125b and miR-99a at least partially restored their 
expression profile after inhibition of HER2 phosphorylation as shown in figure 2.2.2 
B. To select single miRNA, we further performed cell survival assay by restoring 
miR-99a, miR-125b and miR-489 in to MCF7 HER2 cells. Our MTT data 
demonstrate miR-489 can inhibit MCF7 HER2 cells growth compare to miR-99a 
mimic and miR-125b mimic (Figure 2.2 C). miR-489 mimic able to inhibit MCF7 
HER2 cells up to 60% while miR-99a inhibited 20% and there is no significant 
effect of miR-125b mimic on cell proliferation of MCF7 HER2 cells. Based on this 
data, we decided to focus further on the function of miR-489 in HER2 driven breast 






















Figure 2.2: Identification of miRNAs specifically regulated by HER2 
A. Western blot analysis of HER2, p-HER2, p-AKT, Total AKT, p-ERK, 
Total ERK and GAPDH from total protein lystates isolated from MCF7 Vect 
and HER2 cells treated with 2µM Lapatinib (HER2 activation inhibitor).  B. 
qRT-PCR analysis of selective downregulated miRNAs whose expression 
was rescued by lapatinib treatment of MCF-HER2 cells. All data are 
representative of three independent experiments. * p value < 0.05; p value 
< 0.01. C. MTT cell viability assay showing the rate of cell proliferation of 
MCF7-HER2 cells transfected with miR-489 mimic, miR-99a mimic and 
mIR-125b mimic for 72 h. * p=0.0124, ** p<0.0001. 
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2.2.3 DEMONSTRATION OF MIR-489 REGULATION BY HER2 VIA THE 
MAPK PATHWAY 
The miR-489 gene sequence is located in the intronic region of calcitonin 
receptor (CALCR) gene (Figure 2.3). To find whether HER2 affects the expression 
of miR-489 at transcriptional level, we quantified the expression levels of mature 
miR-489, pre-miR-489 and CALCR mRNA in MCF7 vect and HER2 cells using 
qRT-PCR (Figure 2.4 A). Our data demonstrated that expression of CALCR 
mRNA, pre-miR-489 and mature miR-489 are down regulated to a similar extent 
(Figure 2.4 A), suggesting that expression of miR-489 may be controlled at the 
transcription level.  The strong positive correlation between the expression levels 
of CALCR and miR-489 in clinical samples further confirmed this conclusion 





Figure 2.3: Schematic representation of Calcitonin receptor gene showing 
location of miR-489. The schematic showing ~155kb long Calcitonin receptor 
(CALCR) gene, which is located on the chromosome 7. CALCR gene is complex and 
has numerous introns. Pre-miR-489 is located in the intron of CALCR gene. Primer 








Next, to determine the role of a particular signaling pathway in miR-489 
transcriptional regulation, MCF7 HER2 cells were treated with the HER2-
downstream signaling pathways inhibitors targeting NF-κB (Bay-11-7082), PI3K 
(LY294002), AKT1 (SC-66), MEK (U0126), MAPK (PD0325901), SRC (PP2), p38 
(SB-203580), and STAT3 (Stattic) signaling. The qRT-PCR indicated that miR-489 
levels were most significantly rescued by two inhibitors, both targeting the MEK-
ERK signaling (Figure 2.5). These results led us to believe that MEK-ERK signaling 
might be crucial in controlling the miR-489 transcription, although STAT3 and SRC 
pathways may also be involved in its regulation.  
Figure 2.4: Expression of miR-489 is downregulated at transcriptional level 
by HER2 signaling. A. Real-time PCR analysis of calcitonin receptor (CALCR) 
mRNA, pre-miR-489 and mature miR-489 RNA levels in MCF7-HER2 and MCF7-
vect cells. B. Correlation between CALCR mRNA and mature miR-489 in clinical 














To further validate that miR-489 might be regulated by MEK-ERK signaling 
possibly through HER2 down-regulation, we treated cells with si-AKT1 and si-SHC, 
two downstream effectors of HER2 signaling. As shown in the Figure 2.6 A, 
treatment of si-AKT1 or si-SHC resulted in decreased AKT1 expression and 
decreased activation of p-ERK respectively. However, expression of miR-489 was 
rescued only by si-SHC knockdown and not by AKT1 knockdown as shown in 
figure 2.6 B. Furthermore, to understand triggering of which pathway results in 
miR-489 down regulation, we isolated proteins from 13 breast cancer cell lines and 
performed western blotting for p-ERK and pAKT (Figure 2.7 A). Protein expression 
data was quantified and correlated with the expression of miR-489 in each cell line.  
 
Figure 2.5: Effects of HER2-downstream signaling inhibitor 
treatments on the expression of miR-489 in MCF-7 HER2 cells. 
MCF-7 HER2 cells were treated with each of the following inhibitors 
Bay-11 7082 (2µM), Stattic (2µM), SB-203580 (10 µM), PP2 (10 µM), 
PD0325901 (10 µM), U0126 (10 µM), SC-66 (2µM), LY294002 (10 

















The statistical data clearly demonstrated that p-ERK and not p-AKT was 
negatively correlated with the levels of miR-489 in all 13 breast cancer cell lines 
(Figure 2.7 B). Overall, these results clearly demonstrated that miR-489 
expression is transcriptionally regulated at least partially by the HER2-driven 
MAPK downstream signaling. 
 
 
Figure 2.6: Demonstration of miR-489 expression upon inhibition of HER2 
downstream signaling by siAKT1 and siSHC A. Western blot showing the 
effect of siAKT on the expression of AKT, pAKT and effect of siSHC on SHC, 
p-ERK and ERK expression. B. Effects of siRNA-mediated blockage of AKT 














2.2.4 DEMONSTRATION OF MIR-489 EXPRESSION IN PRIMARY BREAST 
CANCER AND RELATIONSHIP OF MIR-489 EXPRESSION WITH DIFFERENT 
CLINICAL PARAMETERS  
To explore the clinical relevance of miR-489 expression in breast cancer, 
we performed quantitative RT-PCR analysis of cDNAs generated from 11 pairs of 
breast cancer and their corresponding adjacent normal tissue. Compared to the 
Figure 2.7: Corelation of miR-489 expression with p-AKT and p-ERK in 13 
different breast cancer cell lines A. Western blot analysis of HER2-signaling 
pathways in breast cancer cell lines B. Pearson analysis of the Correlation 
between p-AKT or p-ERK1/2 and mature miR-489 in breast cancer lines. 
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adjacent normal tissues, primary breast cancers expressed lower levels in 9 out of 
11 pairs of samples (Figure 2.8).  To further validate that loss of miR-489 
expression in breast cancer epithelial cells, we did in situ fluorescent hybridization 
on breast cancer tissue and adjacent normal tissues. Traditional gene expression 
analysis can reveal miRNA expression level in tissue but it cannot reveal the 
location from which structure miRNA is being expressed. High levels of miR-489 
expression were detected in normal epithelia cells and occasionally myoepithelial 
cells, however, the staining signal intensities were weak in the stromal and tumor 
areas (Figure 2.9 A). We also analyzed tissue microarray for miR-489 expression 
by ISH. Similar way, we also observed high miR-489 expression in normal 












Figure 2.8: miR-489 expression in patient samples. Real-time RT-PCR analysis 
of miR-489 in breast cancer tumor tissues and their adjacent normal tissues from 
11 breast cancer patients. *, p value < 0.05. 
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Furthermore, we analyzed the correlation between miR-489 expression 
level and other clinical parameters including overall survival, HER2 status, 
metastasis, grade and stages (Table 2.3). We found that there is an inverse 
correlation between the expression of miR-489 and HER2 in clinical samples as 
indicated by our in vitro data. Loss of miR-489 expression is especially associated 
with tumor in higher grades and higher stages (Table 2.3). We also found that the 
expression levels of miR-489 tend to be lower in HER2-positive and basal 
subtypes compared to both luminal and normal-like subtypes of breast cancer 
(Figure 2.10 A). Given that the expression statuses of miR-489 tend to be 
associated with the aggressive subtypes of breast cancers, we performed the 
Kaplan-Meier survival analysis to further evaluate the prognostic value.   
Table 2.3 The correlation of miR-489 expression with other prognostic 












No.                % No.                % 
HER2 Status   
0.011 Positive 111 68 61.3 43 38.7 
Negative 757 366 48.3 391 51.6 
Grade       
< 0.0001 I-II 396 131 33.1 265 66.9 
III 428 282 65.9 146 34.1 
missing 45 22 48.9 23 51.1 
Distant 
Metastasis 
      
0.0067 
yes 225 130 57.8 95 42.2 
no 645 305 47.3 340 52.7 
Tumor size       
0.0012 <=2 cm 376 160 42.5 216 57.4 
>2cm 492 274 55.7 218 44.3 
Stages       
0.0005 
 
0-I 279 113 40.5 166 59.5 
II 401 210 52.4 191 47.6 
III-IV 73 46 63.0 27 37.0 



















As expected, patients with low miR-489 expression had a relatively poor 
overall survival than those with high miR-489 expression (Figure 2.10 B). In 
addition, multivariate analysis revealed that miR-489 expression was an 
independent prognostic factor to predict overall patient survival (Table 2.4).  
Together, our results support that miR-489 may act as a tumor suppressor and 
Figure 2.9: miR-489 expression by in situ hybridization in patient samples A. 
Both normal duct structure and tumor cells are displayed on same section. Tissues 
are from different breast cancer patients. Normal mammary duct and mammary 
gland express miRNA-489 while absent in tumor tissues. B. ISH analysis of miR-
489 expression in normal breast tissue and adjacent tumor tissues from tissue 
microarray. E, normal epithelial cells; S, stromal cells; M, myoepithelial cells; T, 
tumor cells. 
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Figure 2.10: Correlation of miR-489 expression with different parameter in 
patient samples A. Relative expression levels of miR-489 in breast cancer 
subtypes were compared using the one-way ANOVA analysis. The microarray 
data was extracted from previous publication (de Rinaldis et al., 2013; Dvinge 
et al., 2013). *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001. B. 
Expression status of miR-489 predicts clinical outcome. Patient survival was 
estimated using the Kaplan-Meier method and compared with log-rank tests. 
The Y axis represents the probability of overall survival.  
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Table 2.4. Multivariate Cox proportional hazard regression model of the risk 
of overall survival according to miR-489 expression adjusted for clinic-
pathological factors 
Variables HR CI (95%) P value 
Tumor Size 
(≤2cm/>2cm) 1.016 1.006-1.026 <0.001 
Tumor Grade    
      Grade (I/II) 1.802 0.902-3.601 0.095 
      Grade (I/III) 2.422 1.221-4.804 0.011 
Tumor stage   
     Stage (I/II) 1.205 0.804-1.807 0.367 
     Stage (I/III, IV) 1.860 1.040-3.326 0.036 
HER2 status 
(negative/positive) 1.691 1.232-2.323 0.001 
Lymph node 
(negative/positive) 1.769 1.265-2.476 <0.001 
miR-489 (low/high) 0.606 0.433-0.850 0.004 
 
HR, hazard ratio; CI, confidence interval. 
 
2.2.5 EFFECT OF MIR-489 OVEREXPRESSION ON CELL GROWTH IN VITRO  
To explore the biological function of miR-489 in breast cancer, we 
transiently transfected breast cancer cells with miR-489 mimic or inhibitor and 
measured cell growth by MTT assay. Our results clearly indicated that miR-489 
over expression inhibited cell proliferation in breast cancer cell lines and 
conversely, knockdown of miR-489 increased cell proliferation (Figure 2.11 A). 
However, we didn’t observe significant changes in cellular morphology and the 
number of floating cells. Next, to better understand the role of miR-489 expression 
on cell proliferation, both MCF7 and MDA-MB-231 cells at low density were 
transfected with either the scramble, mimic or miR-489 inhibitor to perform colony 
formation assay. Our results clearly demonstrated that miR-489 affects 
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transforming capability of these cells and yields significantly less colonies 
compared to the cells transfected with scramble miR (Figure 2.11 B). Also, cells 
transfected with inhibitor of miR-489, as predicted had opposite effect and resulted 
in forming more colonies than the cells transfected with scramble miR. Taken 
together, increased expression of miR-489 in breast cancer cells results into 
inhibited cell proliferation and transformation. 
 
 
Figure 2.11: Overexpression of miR-489 in breast cancer cells inhibits cell 
proliferation. A. MTT cell viability assay showing the rate of cell proliferation of 
MCF7-Vect and HER2, BT-474, T47D and MDA-MB-231 cells transfected with miR-
489 mimic or inhibitor for 72 h. B. Colony formation assay on MCF7 and MDA-MB231 
cells transfected with either scramble, mimic miR-489 or inhibitor mir-489 * p<0.05, 
** p value < 0.01.  
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2.2.6 EFFECT OF MIR-489 OVEREXPRESSION ON HER2 SIGNALING 
PATHWAY 
According to the miRwalk pathway target prediction, HER2 pathway can be 
potentially targeted by miR-489. To verify whether miR-489 has any effect on 
HER2 signaling, we transfected MCF7 Vect and HER2 cells with scramble and 
mimic of miR-489 and total protein was isolated after 24 h, 48 h and 72 h. Western 
blotting analysis was performed to examine the HER2 signaling in the transfected 
cells (Figure 2.12 A). Our results indicated that miR-489 mimic gradually impaired 
HER2 signaling as evident by reduced HER2, phospho- HER2, SHP2, phosphor-
Akt and phosphor-ERK in time dependent manner (Figure 2.12 A). To further 
confirm miR-489 effect on HER2 signaling pathway, we transfected scramble, miR-
489 mimic and inhibitor in to MCF7 vector and HER2 cells for 72 h. HER2 signaling 
pathway was checked by performing western blotting. Our result again confirm 
inhibition of HER2 signaling pathway as evident by reduced HER2, phospho- 
HER2, SHP2, phosphor-Akt and phosphor-ERK. Conversely, miR-489 inhibitor 
transfected cells exhibited reversed effect on HER2 signaling compared to miR-
489 mimic.  Moreover, we also observed that expression of total HER2 and SHP2 
were reduced in miR-489 mimic transfected cells and elevated in the miR-489 
inhibitor transfected cells (Figure 2.12 B). To examine the similar effect of mimic-
489 treatment on the expression of HER2, other breast cancer cell lines, AU-565, 
BT-474, HCC-1954 and ZR-75-1 cells were treated with mimic-489 for 72 hours to 
isolate total protein and RNA. Our western blotting data demonstrated that the 
expression of HER2 is decreased in all tested cell types treated with mimic-489  
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Figure 2.12: Demonstration of HER2 signaling pathway upon miR-489 
overexpression A. Effects of miR-489 overexpression on HER2 signaling 
pathway in time dependent manner. WB analysis was performed after MCF7 
Vector/HER2 cells were transfected with mimic-miR-489 for 24, 48 and 72hr. B. 
Effects of miR-489 and inhibitor treatment on HER2-downstream signaling. 
Western blot analysis was performed after MCF-7 vector/HER2 cells were 
transfected for 72 hrs. C, D. Western blot analysis of other breast cancer cell lines 
treated with miR-489 mimic also showed reduction in HER2 and SHP2 protein 
expression E, F. qRT-PCR analysis of SHP2 and HER2 mRNA expression in 
breast cancer cell lines transfected with miR-489 mimic or mock (**p < 0.01). 
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Also, our qRT-PCR data also demonstrated reduced expression of HER2 
at mRNA level upon transfection with miR-489 mimic for 72h in different breast 
cancer cell lines (Figure 2.12 E).  Moreover, Expression of SHP2 is decreased at 
protein and mRNA level in other breast cancer cell lines (Figure 2.15 D, E). 
Together, our results strongly suggested that miR-489 may directly target HER2 









By searching through 3’UTR sequence of HER2, we identified a potential 
partially complementary miR-489 binding site. To demonstrate that this site is 
functional, we performed the dual luciferase assay using reporter constructs 
containing ~400 bp long wt 3’UTR or mutant 3’ UTR of HER2.  Our data showed 
that in the presence of miR-489, luciferase activity of wt HER2 3’UTR and not the 
mutant HER2 3’UTR is significantly reduced (Figure 2.13). These results clearly 
Figure 2.13: miR-489 targets HER2 signaling pathway by directly binding to the 
3’ UTR of HER2 A. A schematic representation of the HER2 mRNA with putative 
miR-489 binding site in the 3’ UTR, where the seed region is highlighted. B. MCF7 
HER2 cells were co-transfected with either of these vectors with miR-489 expressing 
vector or empty vector and renilla expressing vector for 48 h. Firefly luciferase was 
measured for each condition and normalized with renilla luciferase. Normalized 
luciferase activity was compared with WT-3’UTR and Mutant 3’ UTR of HER2.  **, p 
value < 0.01. 
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demonstrated that miR-489 inhibits HER2 expression by directly binding to its 
3’UTR region. Previous, study have validated one of the downstream effector of 
HER2 signaling SHP-2 as the direct target of miR-489 (Arias-Romero et al., 2009; 
Kikkawa et al., 2010).  SHP-2 is known to affect ERK signaling (Bunda et al., 2015; 
Chan, Kalaitzidis, & Neel, 2008). Since p-ERK levels were also inversely correlated 
with the expression of miR-489, we hypothesized that miR-489 affects ERK 
signaling by downregulating the expression of HER2 and SHP2.  
2.2.7 EFFECT OF MIR-489 OVEREXPRESSION ON HER2 AND SHP2 
OVEREXPRESSING CELLS 
Using lentiviral system, we constructed MDA-MB-231 cells over-expressing 
(OE) either HER2 or SHP2 (Figure 2.14 A). Also, level of p-ERK was increased in 
both SHP2 and HER2 OE cells as shown in western blot (Figure 2.14 A). To 
demonstrate the effect of SHP2 or HER2 OE on cell survival against miR-489, 
vector control, SHP2 and HER2 OE MDA-MB-231 cells were transfected with 
either mimic or inhibitor of miR-489. Our MTT data indicated that both SHP2 and 
HER2 OE led to the increased cell survival significantly when compared to the 
vector control cells in the presence of mimic miR-489 (Figure 2.14 B). These 
results overall allow us to create a loop model where, HER2 and SHP2 activates 
ERK signaling which results in cell proliferation and probably inhibits the 
expression CALCR (gene, whose one of the intron contains miR-489) results in 
the inhibition of miR-489 expression.  And miR-489 targets both SHP2 and HER2 








2.2.8 DEMONSTRATION OF NANO PARTICLE MEDIATED DELIVERY OF MIR-
489 MIMIC ON HER2 POSITIVE TUMOR CELL LINE IN ATHYMIC NUDE MICE 
Since miR-489 inhibited cell proliferation and decreased transforming 
capacity of cells to form colony in vitro, we wanted to assess its ability to inhibit 
tumor growth in vivo. To explore the possibility to use miR-489 for therapy, we 
developed a nanoparticle delivery system to deliver miR-489 into tumor cells.  The 
nanoparticle packaged with miR-489 showed similar size distribution as control 




Figure 2.14: Demonstration of miR-489 overexpression effect on SHP2 
and HER2 overexpressing cells A. Western blot showing expression of 
SHP2 and HER2 in SHP2 and HER2 OE MDA-MB231 cells. E. MTT assay 
showing relative cell survival of vector control, SHP2 OE or HER2 OE cells 

























Figure 2.15: Overexpression of miR-489 inhibits tumor growth in vivo. Synthesis 
and characterization of miR-489-delivery nanoparticles. A. Size determination of 
nanoparticle alone or packed with either scramble miR or mimic miR-489 using 
dynamic light scattering. The average size of nanoparticles packed with scramble or 
mimic do not vary significantly.   B. HCC1954 Cells were treated with increasing 
concentration of mimic-489 packed in nano particles for 72 hr. Expression of HER2 
was suppressed with increasing concentration of miR-489. C. Nanoparticle-delivered 
miR-489 inhibits tumor growth. After the tumors were palpable, all 7 tumor sites were 
injected with miR-489 or scramble miRNA encapsulated in nanoparticle every three 
times. The treatment starting day was referred to as ‘Day zero’ in the figure.  D. IHC 
analysis of cells in tumors treated with nanoparticle-delivered miR-489 or scrambled 
miRNA for HER2, SHP2, p-ERK and Ki-67.  E. Graph showing number of Ki-67 
positive cells in tumors treated with nanoparticle-delivered miR-489 or scrambled 
miRNA. ***, p value < 0.001. 
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Treatment of cells with increased concentration of nanoparticle resulted in 
a decrease in HER2 expression levels in a dose-dependent manner (Figure 2.15 
B), indicating that nanoparticles can effectively deliver miR-489 into tumor cells. In 
this xenograft experiment, athymic nude mice were injected with ~2 million 
HCC1954 cells and monitored for tumor growth randomly assigned in 2 groups. 
After tumors were palpable, both group one and two were given the intra-tumor 
injection of nanoparticles packaged with scramble miRNA or mimic-489 
respectively every 3 days. Our tumor volume data indicates that in the last two-
time points tumor sizes of the mimic-489 injected group of mice were significantly 
(p<0.001) smaller than the scramble injected group of mice (Figure 2.15 C). 
Moreover, our IHC data also revealed that HER2 and SHP2 expression was lower 
in miR-489 injected tumors compared to the tumors injected with scramble. Our 
IHC data indicated p-ERK level is reduced in miR-489 injected tumors compared 
to the tumors injected with scramble (Figure 2.15 D). Also, expression of ki-67 was 
significantly lower in miR-489 injected tumors when compared to the scramble 
injected tumors (Figure 2.15 E). Together, these data demonstrated that miR-489 
delivered through nanoparticles affects tumorigenesis in xenografts by decreasing 
cell proliferation at least partially by inhibiting HER2, SHP2, and p-ERK. 
2.3 SUMMARY AND DISCUSSION 
Deregulated miRNA expression can promote tumorigenesis and contributes 
to a variety of cancer phenotypes including uncontrolled cell proliferation, invasion 
and metastasis. HER2-overexpressing breast cancers are generally associated 
with aggressive phenotypes and poor prognosis.  However, how miRNAs are 
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involved in HER2 signaling pathways are not well understood. There are several 
reports on HER2-regulated miRNAs in breast cancers (Bailey, Westerling, & 
Brown, 2015; Y. Lee et al., 2003; Lowery et al., 2009; Mattie et al., 2006) . A 
comparison of our data with these published expression signatures revealed 
several miRNAs previously found to be associated with HER2 such as miR-125, 
miR-99a and miR-21 (Bailey et al., 2015; J. A. Lee, Lee, Lee, Kim, & Bae, 2011; 
Mattie et al., 2006). 
Among many deregulated miRNAs in HER2-overexpressing breast cancer 
cells, miR-489 expression may be directly regulated by HER2 signaling since 
treatment with HER2/EGFR dual inhibitor lapatinib can significantly reverse miR-
489 expression status in HER2-positive breast cancer cells. Loss of miR-489 
expression in HER2-positive breast cancer cells suggests that miR-489 might have 
tumor suppressive function. Previously, it was already known that miR-489 
functions as a tumor suppressor gene in hypopharyngeal squamous cell 
carcinoma (HSCC)(Kikkawa et al., 2010). In this study, screening for miRNAs that 
inhibited cancer cell proliferation was performed. Among different miRNAs, miR-
489 stood out, as its overexpression inhibited cell growth in all cell lines 
examined(Kikkawa et al., 2010).  Consistently, we show that restoration of miR-
489 in HER2-overexpressing breast cancer cells strongly inhibits cell proliferation 
both in vitro and in vivo. Different from many tumor suppressors that normally 
induce cell cycle arrest and apoptosis, miR-489 dramatically reduced ki67-positive 
population but didn’t induce apoptosis. Conversely, transfection of miR-489 
inhibitor can further increase cell proliferation rate which is evidenced by increased 
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cell population in S phase. These data indicated that miR-489 may be directly or 
indirectly involved in regulating cell cycle progression.  
In a previous screening for microRNAs which are essential for HER2 
positive breast cancer cell growth, miR-489 has been identified as one the potential 
candidates to attenuate HER2 signaling but the underlying mechanism remains 
unknown(Leivonen et al., 2014). In this study, we for the first time demonstrated 
that HER2 is a bona fide target of miR-489 by the following evidences. First, 
overexpression of miR489 results in down-regulation of HER2 in several breast 
cancer cell lines. In a complementary experiment, transient transfection of miR-
489 inhibitor can increase the protein levels of HER2. Secondly, a putative miR-
489 binding site is identified in the 3’UTR of HER2 mRNA. Thirdly, the expression 
levels of miR-489 is inversely correlated with HER2 expression status in clinical 
breast cancer samples. Identification of HER2 as a new target in breast cancer 
cells may shed light on the function of miR-489 in breast tumorigenesis. It should 
also be kept in mind that besides HER2, miR-489 may target many other target 
genes as well. For example, miR-489 has been shown to directly target other 
oncogenes such as Shp2 in HSCC(Kikkawa et al., 2010), SMAD3 in breast cancer 
(Jiang et al., 2014), AKT3 in ovarian cancer (Wu et al., 2014) and Dek in mouse 
muscle stem cells (Cheung et al., 2012; Wu et al., 2014). The Shp2 gene is unusual 
in that it promotes the activation of RAS–MAPK signaling pathway downstream of 
EGFR family receptors(Matozaki, Murata, Saito, Okazawa, & Ohnishi, 2009; Mohi 
& Neel, 2007). We have also confirmed that miR-489 can directly downregulate 
SHP2 expression in breast cancer cells. One could envisage that miR-489 can 
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dramatically modulate HER2 signaling networks via simultaneously targeting 









Understanding the signaling cross-talk between miR-489 and HER2 indicate 
that the HER2-SHP2-MAPK signaling axis and miR-489 form a double-negative 
regulation loop to regulate cell proliferation in breast cancer (Figure 2.16). Double-
negative feedback loop involving microRNAs and their targets have been observed 
previously(Bracken et al., 2008; Fang et al., 2011; Johnston, Chang, Etchberger, 
Ortiz, & Hobert, 2005; X. Yang et al., 2010). As a general model, the double-
negative feedback loop is advantageous in allowing the system to remain 
Figure 2.16: General feedback loop model between HER2 and miR-489. 
HER2 signaling through SHP2 and ERK promotes cell proliferation and inhibits 
miR-489 expression, whereas miR-489 downregulates both HER2 and SHP2 
directly to inhibit cell proliferation. 
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reversible. This feature is evident in the previous observations that the switching 
ability between epithelial and mesenchymal states can be regulated by the 
ZEB/miR-200 feedback loop(Bracken et al., 2008). Here, it is likely that the HER2-
SHP2-MAPK/miR-489 feedback loop is involved in regulation of 
quiescence/proliferation phenotypical transition in cancer cells. HER2 expression 
is associated with higher cell proliferation, whereas miR-489 expression may be 
associated with slow proliferation or quiescent status(Cheung et al., 2012). It 
remains unknown whether the expression ratio of HER2/miR-489 determines the 
overall cell proliferation rate of a tumor or tumor heterogeneity with mixed cell 
population with high/slow proliferation rates. Given that a double-negative 
feedback loop generally allows the maintenance of bi-stable states, we tend to 
believe that the ratio of HER2/miR-489 is critical for generation of tumor 
heterogeneity and determination of tumor behaviors.   
Although our clinical data shows that miR-489 expression is lower in HER2-
positive tumors, its expression can be downregulated in many human breast 
cancers independent of their HER2 expression status. Because miR-489 is mainly 
regulated via the MEK-ERK pathway which can be activated by many 
overexpressing oncogenes or receptors or cytokines. For example, expression of 
multiple members of the epidermal growth factor receptor family (HER1, HER2, or 
HER3) and estrogen receptor is present in most breast cancer cells, and these 
receptors have all been shown to activate the MEK-ERK pathway(Ferrer-Soler et 
al., 2007; Filardo, Quinn, Bland, & A. Raymond Frackelton, 2000; Santen et al., 
2008). This may explain why miR-489 is broadly down-regulated in breast cancer 
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cells compared to their adjacent normal tissues, especially in HER2-positive and 
basal subtypes of breast cancers. It was worth mentioning that hyperactivation of 
ERK1/2/MAPK signaling occurring downstream of EGFR or HER2 in breast cancer 
can induce loss of ER expression leading to establishment of ER-negative 
phenotype (Oh et al., 2001). Cancers with hyperactivation of ERK1/2/MAPK 
signature are associated with adverse clinical features and especially enriched for 
basal-like and HER2-positive subtypes (Miller, Clarke, Koru-Sengul, Brinkman, & 
El-Ashry, 2015). Consistently, our data showed that the expression levels of miR-
489 are lower in basal-like and HER2-positive subtypes compared to luminal 
subtypes of breast cancers. Given that the expression levels of miR-489 is strongly 
correlated with tumor aggressive phenotypes, it raises the possibility that targeting 
miR-489 as a therapy may be of benefit not just in HER2/neu-overexpressing 
tumors but also in a broader subset of patients. 
This research is taken from published paper entitle A novel double-negative 
feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis 
regulates breast cancer cell proliferation and tumor growth. (Patel et al., 2016)
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CHAPTER 3 
THE ROLE OF MIR-489 IN CELL CYCLE REGULATION 
3.1 INTRODUCTION 
Triple-negative breast cancers (TNBCs) are characterized by lack of 
estrogen and progesterone nuclear receptor (ER/PR) expression, as well as lack 
of the human epidermal growth factor receptor-2 (HER2) (Song et al., 2017). Gene 
expression analysis also suggests TNBC shares similar characteristics as basal 
type breast cancer (Ossovskaya et al., 2011). Triple negative breast cancer is an 
aggressive breast cancer subtype that has a high rate of proliferation and 
metastasis in comparison to other subtypes of breast cancer (Song et al., 2017). 
Patients with TNBC typically face poor prognoses due to a lack of molecular- 
targeting therapies for TNBC, making the disease difficult to treat. Metastatic 
TNBC has a very high mortality rate with a median survival time of patients 13 
months for diagnosed patients. The high mortality rate is maintained in spite of 
treatment with systemic chemotherapy, which is the only treatment option due to 
a lack of validated actionable molecular targets for therapeutic use (Song et al., 
2017). A better understanding of pathological mechanisms of TNBC onset and 
progressions is required. A greater understanding of the molecular mechanisms of 
TNBC may facilitate the identification of therapeutic targets, as well as predictive 
or prognostic biomarkers, and enable an understanding of the mechanisms of 
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response. Relapses are frequent and resistance to the chemotherapeutic agents 
is often encountered in the metastatic setting. Thus, the idea of identifying driver 
molecular alterations present in TNBC has stimulated research to find aberrant 
signaling networks that may be targeted with alternative approaches.  
Dysregulation of cell cycle- related genes in has been found in the TNBC 
subtype. An analysis from human cancers revealed that genes encoding cyclins 
and CDKs are most frequently amplified loci. Also, several studies based on 
mouse genetic models have concluded the role of cyclins and CDKs in tumor 
development and maintenance(Asghar, Witkiewicz, Turner, & Knudsen, 2015; S. 
Lim & Kaldis, 2013). Several CDK pan inhibitors have been discovered and 
approved by FDA for treating cancer patients. CDK4/6 inhibitors (palbociclib, 
abemaciclib and ribociclib) have been through clinical trials; however, they didn’t 
change overall survival of patients because redundant CDKs and cyclins 
compensated for the inhibition of CDK4 and CDK6, thereby permitting tumor 
progression(Hydbring et al., 2017; Otto & Sicinski, 2017). Because of this issue, it 
is necessary to find new agents that can target multiple genes involved in cell cycle 
regulation. This could be more effective in preventing compensatory cyclins and 
kinases.  
The role of miRNAs in controlling cell proliferation by targeting several 
cyclins and kinases involved in cell cycle regulation has been established(Bueno 
& Malumbres, 2011; Yu et al., 2010). More specifically, tumor suppressor miRNAs 
induce cell cycle arrest by downregulating multiple components of the cell cycle 
machinery. miR-193b has been identified by genome wide analysis as one of the 
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candidate miRNAs can target multiple cyclins and CDKs (Hydbring et al., 2017; 
Tagscherer et al., 2016). This study has demonstrated miR-193b can inhibit growth 
of several cancer cell lines, specifically TNBC cell lines. In another study, it has 
been demonstrated miR-766 overexpression decreases cell proliferation and 
colony formation ability by arresting cells in G2 phase by directly targeting MDM4, 
a negative regulator of p53(Q. Wang, Selth, & Callen, 2017). It has also been 
demonstrated miR-506 overexpression significantly reduces ovarian cancer 
growth by directly targeting CDK4/6 and miR-200b inhibits esophageal squamous 
cell carcinoma growth by arresting cell cycle at G2/M phase by directly targeting 
CDK2 and PCNA-associated factor(Liu et al., 2014; Zhang et al., 2016).  
In previous studies, we demonstrated miR-489 overexpression inhibits 
proliferation and colony formation ability of different breast cancer cell lines by 
directly inhibiting HER2 signaling pathway through direct targeting of HER2 and 
SHP2. In order to find the role of miR-489 in breast cancer, we have correlated 
miR-489 expression with different subtypes of breast cancer and found the lowest 
expression of miR-489 in basal- type breast cancer. We observed miR-489 
overexpression dramatically affected proliferation of MDA-MB-231 cells. MDA-MB-
231 cells are triple negative breast cancer cell lines, which do not require the HER2 
signaling pathway for growth. So, we hypothesized miR-489 may inhibit other 
important pathways which are necessary for cell proliferation. In this study, we 
demonstrated how miR-489 also regulates the cell cycle by regulating key kinases 




3.2.1 EFFECT OF OVEREXPRESSION OF MIR-489 ON TRIPLE NEGATIVE 
BREAST CANCER CELL LINES GROWTH  
In previous studies, we have observed low miR-489 expression in basal- 
type of breast cancer patients compared to other types of breast cancer. We also 
observed that the MDA-MB-231 cell line exhibited an aggressive cytostatic effect 
upon mimic-miR-489 transfection. Based on these observations, we hypothesize 
miR-489 mimic might induce aggressive cytostatic effect in TNBC cell lines. To 
observe the effect of miR-489 mimic on breast cancer cell lines, we transiently 
transfected miR-489 mimic in T47D, MCF7, BT474, ZR-75-1, HCC1954, 
HCC1569, MDA-MB-231, BT549 and HS578t cells and measured cell growth by 
MTT assay as shown in figure 3.1. Our results clearly indicated that miR-489 over 
expression induced significant cytostatic effect on TNBC cell lines compared to 
other types of breast cancer cell lines. We ran a statistical test between percent 
viability of TNBC cells lines compared with rest of the group, and our test result 
clearly demonstrates significant difference between TNBC cell lines with mimic-
miR-489 and rest of the cell lines with mimic-miR-489 (P<0.0001). Next, to better 
understand the role of miR-489 expression on TNBC cell lines, MDA-MB-231, BT-
549 and HS578T cells were transfected with mimic and an inhibitor of miR-489, 
and seeded at low density to observe the long-term effect of miR-489 mimic to 
perform colony formation assay. Our results clearly demonstrated that miR-489 
affects the transforming capability of these cells where cells transfected with miR-
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489 mimic yielded significantly less colonies than the control. Conversely, more 



















To further confirm effect of miR-489 mimic on TNBC cell lines, real time cell 
analysis was performed on MDA-MB-231 cells for 96hr. The real-time cell analysis 
assay is more accurate than the MTT assay. This assay clearly demonstrated 90 
Figure 3.1: Demonstration of growth inhibition by miR-489 mimic in 
different breast cancer cell lines. MTT assay demonstrating growth of 
T47D, MCF7, BT474, ZR-75-1, HCC1954, MDA-MB-231, BT-549 and 
HS578t breast cancer cell lines in presence of miR-489 mimic 72hr post 
transfection. ** P=0.0054, ** P=0.0065, ** P=0.0074, * P=0.0366, * P=0.0299, 
*** P=0.0007, *** P<0.0001, *** P=0.0003, *** P<0.0001. Statistical test was 
run between percent viability in presence of mimic-miR-489 between TNBC 
cell lines (MDA-MB-231, BT549 and HS578t) and rest of the group (T47D, 
MCF7, BT474, ZR-75-1, HCC1954 and HCC1569). *** P<0.0001.  
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percent growth inhibition upon miR-489 mimic transfection (Figure 3.2 B). Overall, 





















Figure 3.2: Demonstration of growth inhibition by miR-489 mimic in TNBC 
lines by using colony formation and real-time cell analysis. A. Colony 
formation assay on HS578t, BT549 and MDA-MB-231 cells transfected with either 
scramble, mimic miR-489 or inhibitor mir-489. B. Real-time cell analysis of MDA-
MB-231 cells in presence of either scramble and miR-489 mimic.  
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3.2.2 DEMONSTRATION OF GEO ANALYSIS FROM DYSREGULATED GENES 
BETWEEN T47D SCR AND T47D MIMIC-MIR-489 TRANSFECTED CELLS 
Previously, we and others have reported miR-489 exhibits its cytotoxic 
effect by targeting HER2, SHP2, SMAD3 and SPIN1 in breast cancer cells. After 
observing significant cytotoxic effect in TNBC cell lines, we wanted to further our 
findings and identify more genes that are responsible for significant cytotoxic 
effect. To find out genes associated with miR-489, microarray analysis was 
performed with RNA isolated from T47D cells that were transfected with scramble 
and miR-489 mimic for 72 hr. Before performing microarray, qRT-PCR was 
performed to confirm that miR-489 influences previously observed genes, HER2 
and SHP2 (Figure 3.3 A). We previously observed HER2 and SHP2 down- 
regulation at mRNA level upon miR-489 mimic transfection. Similarly, we observed 
down regulation of these two genes in T47D cells transfected with miR-489 mimic. 
To validate the microarray data, we analyzed LAPTM4B, Rac2, KRT7, TXNDC5, 
Erbb3, GNB1 and CADM1 genes by qRT-PCR, all of which were suggested as top 
down regulated genes by microarray. The qRT-PCR data suggested a similar trend 
as the microarray data (Figure 3.3 B). We performed GO analysis by using the 
microarray data and found dysregulated genes upon miR-489 overexpression are 
associated with the cell cycle, cell cycle checkpoints, cell cycle arrest, M/G1 
transition, G1/S transition and the mitotic cell cycle pathway (Figure 3.3 C). Overall, 























3.2.3 EFFECT OF MIR-489 OVEREXPRESSION ON CELL CYCLE ARREST 
 Since GO analysis from microarray data indicated genes associated with 
mitotic cell cycle, G1/S transition, M/G1 transition, cell cycle arrest, cell cycle 
checkpoint and cell cycle are significantly dysregulated in T47D cells transfected 
Figure 3.3: Demonstration of microarray analysis from T47D cells tranfected 
with either scramble or miR-489 mimic. A. qRT-PCR analysis demonstrating 
expression of SHP2 and HER2 in the T47D cells transfected with either scramble or 
miR-489 mimic. B. qRT-PCR analysis demonstrating expression of LAPTM4B, Rac2, 
KRT7, TXNDC5, Erbb3, GNB1 and CADM1 in the T47D cells transfected with either 
scramble or miR-489 mimic. C. GO analysis was performed by using dysregulated 
genes from microarray data obtained from T47D cells transfected with either 
scramble or miR-489 mimic.  
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with miR-489 mimic, we wanted to first observe the effect of miR-489 
overexpression on cell cycle transition by performing cell cycle analysis. Cell cycle 
analysis was performed on MDA-MB-231 and BT-549 cells transfected with miR-
489 mimic for 67 hr (Figure 3.4 A, D). Our cell cycle analysis data indicated 
significant G2/M arrest in both of the cell lines upon miR-489 mimic transfection 
(Figure 3.2.4 A, D). MDA-MB-231 cells have demonstrated 2 fold increase in G2/M 
phase upon miR-489 mimic transfection (Figure 3.4 B). We also observed 3 to 4 
fold more cells in G0 phase upon miR-489 mimic transfection, which is an indicator 
of apoptosis (Figure 3.4 C). Similar results have been observed with BT-549 cells 
as well. We observed 3 to 4 fold increase in G0 phase and 1.5 fold increase in 
G2/M phase (Figure 3.4 E, F). To further validate our results, we performed dose 
dependent analysis with MDA-MB-231 cells transfected with 11.42nM, 20.5nM and 
28.5nM miR-489 mimic for 67 hr (Figure 3.5). Our cell cycle analysis data indicates 
dose- dependent G2/M arrest upon miR-489 mimic transfection. Our data indicates 
significant G2/M arrest upon miR-489 mimic transfection. It is necessary to 
decipher whether this is mitotic arrest or G2 arrest. Phosphorylation at Serine 10 
on Histone 3 protein is an indicator of M phase arrest. To check whether miR-489 
mimic transfection is inducing M phase arrest, we performed western blotting to 
check phospho-histone 3 with protein isolated from MDA-MB-231 and BT-549 
transfected with miR-489 mimic, miR-489 inhibitor and scramble for 67 hr (Figure 
3.6 A). Our western blotting data indicates significant up- regulation of phospho- 
histone 3 in mimic-miR-489 transfected cells compared to scramble and inhibitor 

























Figure 3.4: Demonstration of cell cycle analysis in presence of miR-489 mimic. 
A. Cell cycle analysis of MDA-MB-231 cells transfected with either scramble or miR-
489 mimic for 67 hr. B. Sub G0 phase between scramble and mimic-miR-489 
transfected MDA-MB-231 cells. *** P<0.0001 C. G2/M phase of cell cycle between 
scramble and mimic-miR-489 transfected MDA-MB-231 cells. *** P<0.0001 D. Cell 
cycle analysis of BT-549 cells transfected with either scramble or miR-489 mimic for 
67 hr. E. Sub G0 phase between scramble and mimic-miR-489 transfected BT-549 
cells. *** P<0.0001 F. G2/M phase of cell cycle between scramble and mimic-miR-


















Next, we wanted to check whether miR-489 mimic is inducing cell death 
through apoptosis. To check this, we performed western blotting to analyze 
cleaved caspase 3 protein by using protein isolated from MDA-MB-231 and BT-
549 cells transfected with mimic-miR-489 and inhibitor of miR-489 (Figure 3.6 B). 
Our western blotting data indicates significant up- regulation of cleaved caspase 3 
in mimic-miR-489 transfected cells. Overall, these data suggest miR-489 mimic is 
inducing significant G2/M mitotic arrest and inducing apoptosis in TNBC cell lines. 
Figure 3.5: Demonstration dose dependent G2/M arrest in MDA-MB-231 
cells transfected with miR-489 mimic. Cell cycle analysis was performed with 
MDA-MB-231 cells transfected with 11.42 nM, 20.5nM, 28.5nM either scramble 




3.2.4 EFFECT OF MIR-489 OVEREXPRESSION ON DIFFERENT CELL CYCLE 
REGULATORY PROTEINS IN TNBC CELL LINES  
It is necessary to identify molecular targets through which miR-489 is 
inducing cell cycle arrest. To find whether miR-489 down regulates any cell cycle 
regulatory proteins, we performed western blotting with proteins isolated from 
scramble, miR-489 mimic and miR-489 inhibitor transfected MD-MBA-231, 
HS578T and BT-549 cells. We analyzed cyclinA, CyclinB1, cyclinE2, CDK1 and 
Figure 3.6: Demonstration of mitotic arrest and death in MDA-MB-231 and BT-
549 cells in presence of miR-489 mimic. A. Western blot analysis demonstrating 
phospho histone 3 in MDA-MB-231 and BT-549 cells transfected with either 
scramble, mimic-miR-489 or inhibitor-miR-489. B. Western blot analysis 
demonstrating cleaved caspase 3 in MDA-MB-231 and BT-549 cells transfected with 
either scramble, mimic-miR-489 or inhibitor-miR-489.  
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FOXM1 proteins (Figure 3.7). Our western blot data indicates down regulation of 
cyclinA, cyclinB1, cyclinE2, CDK1 and FOXM1 upon miR-489 mimic transfection 
in all demonstrated cell lines. Conversely, we observed up- regulated expression 
upon endogenous miR-489 inhibition. Next, we wanted to determine whether 
CDK1 or FOXM1 are direct targets of miR-489. To find this answer, we analyzed 
3’-UTR of FOXM1 for binding site for miR-489-3p. By searching through 3’UTR 
sequence of FOXM1, we identified a potential partially complementary miR-489 
binding site (Figure 3.8 A). To demonstrate that this site is functional, we performed 
the dual luciferase assay using reporter constructs containing ~400 bp long wt 
3’UTR or mutant 3’ UTR of FOXM1. 
 
Figure 3.7: Demonstration of different cell cycle regulators in presence of 
either scramble, mimic-miR-489 or inhibitor-miR-489 by western blotting. 
Western blot data demonstrating CyclinA2, CyclinB1, CyclinE2, CDK1 and 
FOXM1 expression in MD-MBA-231, HS578t and BT549 cells transfected with scr, 




  Our data showed that in the presence of miR-489, luciferase activity of wt 
FOXM1 3’UTR and not the mutant FOXM1 3’UTR is significantly reduced (Figure 
3.8 B). These results clearly demonstrated that miR-489 inhibits FOXM1 
expression by directly binding to its 3’UTR region. 
Figure 3.8: miR-489 targets FOXM1 by directly binding to the 3’- UTR 
of FOXM1. A. A schematic representation of the FOXM1 mRNA with 
putative miR-489 binding site in the 3’ UTR B. HEK293 cells were co-
transfected with either of these vectors with miR-489 expressing vector 
or empty vector and renilla expressing vector for 48 h. Firefly luciferase 
was measured for each condition and normalized with renilla luciferase. 
Normalized luciferase activity was compared with WT-3’UTR and Mutant 
3’ UTR of FOXM1.  **, p value < 0.01, *, p <0.0299. 
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3.2.5 EFFECT OF CDK1 AND FOXM1 OVEREXPRESSION ON MIR-489 
INDUCED GROWTH AND CELL CYCLE ARREST  
 Next, we wanted to perform gain of function assay with CDK1 and FOXM1. 
To find out how important CDK1 and FOXM1 are in miR-489 mediated G2/M arrest 
and inhibition of cell proliferation. By using pCMV-CDK1 vector, we generated 
MDA-MB-231 CDK1 overexpressing cells, confirmed by our western blot data 
(Figure 3.9 A). Since pool has significant up regulation of CDK1, we used pool for 
subsequent experiment. To demonstrate the effect of CDK overexpression on cell 
survival against miR-489, vector control, CDK1 overexpressing MDA-MB-231 cells 
were transfected with either mimic-miR-489 or scramble. Our MTT data indicated 
that CDK1 OE led to significantly increased cell survival when compared to the 
vector control cells in the presence of mimic miR-489 (Figure 3.9 B). We then 
wanted to test the effect of CDK1 overexpression on miR-489 mediated G2/M 
arrest. Our cell cycle analysis data indicated that CDK1 OE led to decreased G2/M 
arrest (Figure 3.9 C). By using pCMV-FOXM1 vector, we generated MDA-MB-231 
FOXM1 overexpressing cells. Our western blot data demonstrated overexpression 
of FOXM1 in MDA-MB-231 cells (Figure 3.10 A). Since both pool has significant 
up- regulation of FOXM1, we used both pool for subsequent experiment. To 
demonstrate the effect of FOXM1 overexpression on cell survival against miR-489, 
vector control, FOXM1 overexpressing MDA-MB-231 cells were transfected with 
either mimic or inhibitor of miR-489. Our MTT data indicated that FOXM1 OE led 
to a significant increase in cell survival when compared to the vector control cells 
in the presence of mimic miR-489 (Figure 3.10 B). We then tested the effect of 
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FOXM1 overexpression on miR-489 mediated G2/M arrest. Our cell cycle analysis 













Figure 3.9: Demonstration of miR-489 overexpression effect on CDK1 
overexpressing MDA-MB-231 cells A. Western blot showing expression of 
CDK1 in CDK1 OE MDA-MB231 cells. B. MTT assay showing relative cell survival 
of empty control or CDK1 OE cells transfected with scramble or mimic miR-489 
***, P=0.0001 C. Cell cycle analysis showing percent cells in G2/M phase of empty 
control or CDK1 OE cells transfected with scramble or mimic. ***, P=0.0004 
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Overall, these data indicate miR-489 mediated down- regulation of CDK1 and 
FOXM1 is important for its effect on cell cycle arrest. Also, the data indicates both 















Figure 3.10: Demonstration of miR-489 overexpression effect on FOXM1 
overexpressing MDA-MB-231 cells A. Western blot showing expression of 
FOXM1 in FOXM1 OE MDA-MB231 cells. B. MTT assay showing relative cell 
survival of empty control or FOXM1 OE cells transfected with scramble or mimic 
miR-489 **, p<0.01; **, p<0.01 C. Cell cycle analysis showing percent cells in G2/M 
phase of empty control or FOXM1 OE cells transfected with scramble or mimic. **, 




3.3 SUMMARY AND DISCUSSION 
Role of miRNAs in the pathogenesis of cancer was suggested after their 
discovery in humans. Using miRNA analysis between two isogenic cell lines MCF7 
vector and HER2, we previously demonstrated a double negative feedback loop 
between HER2-SHP2-MAPK and miR-489 which regulate breast cancer 
proliferation. In that report, we noticed miR-489 restoration inhibit HER2 positive 
and TNBC cell lines growth. We defined how miR-489 acts as tumor suppressor 
in HER2 positive breast cancer cell lines however its mechanism in TNBC remains 
elusive. The current study uncovers a role of miR-489 in promoting apoptosis by 
suppressing cell cycle progression and cell growth in TNBC cell lines. A key cell 
cycle regulator CDK1 and FOXM1 are identified as target and functional mediators 
of miR-489. The miR-489/CDK1/FOXM1 axis is very critical for maintaining cell 
growth of TNBC cell lines.  
Although many studies have pointed out miR-489 as tumor suppressor 
miRNA by inhibiting very key regulatory proteins involve in tumor progression, but 
it’s role in cell cycle regulation hasn’t been elucidated yet.  One of the hallmarks of 
cancer is unbridled cell proliferation, often manifesting through alterations of the 
cell-cycle machinery, including cyclin-dependent kinases (CDKs) and their 
cognate catalytic partners, the cyclins. When we performed cell proliferation assay 
with several breast cancer cell lines, we observed very significant effect on triple 
negative breast cancer cell lines. Also, miR-489 restoration inhibited colony 
formation ability of TNBC cell lines significantly. One possibility explanation is that 
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TNBCs were shown to be particularly dependent on CDKs for cancer cell survival. 
Consistent with this hypothesis, our GO analysis also suggest miR-489 restoration 
has significantly dysregulated cell cycle regulatory genes.  
By analyzing different cell cycle regulatory kinase and cyclins, we found 
CDK1, CyclinA2, CyclinB1, CyclinE1 and FOXM1 down regulated upon miR-489 
overexpression. It has been demonstrated triple negative breast cancer cell lines 
are sensitive to dinaciclib. In the same study, it has been shown MDA-MB-231 and 
BT549 are highly sensitive to siCDK1(Rajput et al., 2016). Also, siCDK1 was able 
to diminish their proliferation and colony formation ability in vitro. Consistent with 
their observation, we also observed similar sensitivity with miR-489 mimic which 
down regulated CDK1. Consistently, they also observed G2/M arrest and increase 
cell population in G0 phase with siCDK1. In current study, we have observed miR-
489 mimic has arrest cells in G2/M phase and also increase cell population in G0 
phase.  
Due to lack of well-defined targets, developing targeted therapies against 
triple negative breast cancer has been challenging. However, it has been 
demonstrated dysregulated MYC pathway that underlies majority of triple negative 
breast cancer(Horiuchi et al., 2012). Several studies have indicated MYC 
dependent cells are highly dependent on survivin (BIRC5) an inhibitor of apoptosis 
which require CDK1 for stability. In absence of CDK1, survivin degrades quickly 
which induce dramatic cell death(Horiuchi et al., 2012). Because of this inhibition 
of CDK1, induce synthetic lethality in MYC dependent cells. In initial studies have 
pointed out CDK inhibitors can act as potent therapeutic in triple negative breast 
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cancer but one study has demonstrated targeting CDK1 but not CDK2 and CDK4/6 
induce selective lethality in MYC- dependent breast cancer cells(Kang, Sergio, 
Sutherland, & Musgrove, 2014). Since miR-489 can down regulate CDK1, miR-
489 can be prove as potent agent for treating triple negative breast cancer. Also, 
one study has pointed out compromised CDK1 activity sensitizes BRCA-proficient 
cancers to PARP inhibition(Johnson et al., 2011). It will be interesting to study 
whether miR-489 restoration also sensitizes BRCA-deficient cells to PARP 
inhibitors.  
Several studies have demonstrated cyclinB1 down regulation upon siCDK1 
transfection. Similar way, we have observed cyclinB1 also goes down with miR-
489 overexpression. However, it is important question how cyclinA2 and cyclinE1 
also goes down with miR-489 overexpression. This data also indicate other CDKs 
also can be target of miR-489. Further study is warranted to find other miR-489 
targets which are require for cell cycle regulation.  
We observed significant blockade of cell cycle in G2/M phase upon miR-
489 overexpression. Studies have demonstrated dynamic distribution of 
phosphorylated Histone H3 on Ser10 in cells during mitosis(D. W. Li et al., 2005; 
Prigent & Dimitrov, 2003). Phospho-H3 begins at early prophase and it stays till 
cytokinesis. Our results also have indicated strong presence of Phospho-H3 upon 
miR-489 restoration in TNBC cell lines. This may suggest miR-489 overexpression 
arrest cells in mitotic phase. It is interesting to study at which specific phase of 
mitosis miR-489 arrest cells. Also, further study is warranted whether miR-489 
targets any key important protein which govern mitosis process.  
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Several studies have pointed out high expression of FOXM1 in TNBC 
patients and have stronger correlation with higher tumor grade(Hamurcu, 
Kahraman, Ashour, & Ozpolat, 2017). Also, FOXM1 overexpression has been 
associated with poor prognosis in TNBC patients(J. J. Lee et al., 2016). Several 
studies have pointed out FOXM1 regulates several essential genes which are 
necessary for mitosis progression. Moreover, FOXM1 has phosphorylation site at 
Serine-251 and disruption at Ser-251 is associated with reduced expression of 
G2/M phase gene and impaired mitotic progression(Y. J. Chen et al., 2009). In this 
study, first time we are reporting miR-489 can down regulate FOXM1 by directly 
binding to its 3’-UTR regions. Thus, miR-489 also can inhibit one of key oncogenic 
transcription factor which regulate expression of several cell cycle related gene. 
Studies also have pointed out FOXM1 role in epithelial to mesenchymal transition 
(EMT)(Patel et al., 2016; Tan et al., 2016). Further study is warranted to find role 
of miR-489 in EMT process.   
In conclusion, this study has uncovered that miR-489, a frequently 
deregulated tumor suppressor miRNA in wide spectrum of cancers, suppresses 
multiple key cell cycle regulators and mitigate cell growth by arresting TNBC cell 
lines in to G2/M phase of cell cycle. CDK1 and FOXM1, two significant prognostic 
markers in triple negative breast cancers, are identified as direct targets of miR-
489. This research highlights miR-489 as a promising therapeutic target in triple 
negative breast cancer.  
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CHAPTER 4 
OVEREXPRESSION OF MIR-489 DERAILS MAMMARY HIERARCHY 
STRUCTURE AND INHIBITS HER2/NEU INDUCED TUMORIGENESIS 
4.1 INTRODUCTION 
Breast cancer is a highly heterogenous disease based on phenotypic and 
functional features.  Gene expression profiling of human breast cancer and mouse 
mammary tumor models broadly classifies breast cancer cells as either luminal- 
like or basal.(Jeselsohn et al., 2010); MMTV-Her2 mouse model is classified as a 
luminal type breast cancer. MMTV-Her2 mammary tumors have been shown to 
share gene expression profiles with luminal progenitor cells(E. Lim et al., 2010). 
Some of the altered progenitors may function as tumor initiating Cells (TICs), which 
are responsible for Her2 mediated mammary tumors(E. Lim et al., 2010; Lo et al., 
2012; Vaillant, Asselin-Labat, Shackleton, Lindeman, & Visvader, 2007). In fact, 
the cell-of-origin hypothesis suggests that certain breast cancer arise from 
transformation of stem or progenitor cells(Visvader, 2011; Visvader & Lindeman, 
2012).  Therefore, identifying molecular drivers that regulate the stem-progenitor 
axis may provide insight into the initiation and progression of HER2 mediated 
tumorigenesis.  
miRNAs have been found dysregulated and regulating mammary stem-
progenitor axis by controlling diverse pathway. For instance, miR-146b has been 
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found highly express in mammary gland cells during pregnancy and lactation 
phage and high expression of miR-146b is required for maintenance of pregnancy-
derived mammary luminal alveolar progenitors by directly targeting stat3b(Elsarraj 
et al., 2013). miR-221 is also found highly express in stem-like and myoepithelial 
cells compare to luminal cells and Knockdown of miR-221 increased luminal cells. 
miR-221 expression regulates EMT process by targeting ATXN1(Ke et al., 2015). 
Similarly, miR-182 and miR-193b also have been found regulating mammary stem-
progenitor axis(Martinez-Ruiz et al., 2016; Yoo et al., 2014). miR-184 also highly 
express in ducts compare to highly proliferative pubertal terminal end bud and its 
expression lost in mouse mammary tumor. Restoration of miR-184 inhibited 
proliferation and self-renewal of TNBC cell lines in vivo(Phua et al., 2015). 
It has been demonstrated that miR-489 plays a vital role in breast cancer 
progression and chemo-resistance by targeting several important genes including 
Smad3, Spin1, Bcl2 and AKt3(X. Chen et al., 2016; Jiang et al., 2014). In past 
reports, we demonstrated that Her2-regulated miR-489 expression through the 
MAPK pathway and miR-489 negatively regulates the Her2 signaling pathway by 
targeting HER2 and Shp2(Patel et al., 2016). Also, miR-489 plays a critical role in 
muscle stem cell maintenance, where it has been shown to maintain stem cell in 
a quiescent state by targeting DEK1(Cheung et al., 2012). Although many studies 
have reported tumor suppressor roles of miR-489 in breast cancer, its influence on 
mammary stem cells, mammary gland development, tumor initiation and 
metastasis remains elusive.  
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In this study, we dissect the role of miR-489 in the mammary stem-
progenitor axis and Her2 induced TICs. To study the role of miR-489 in mammary 
gland development and Her2 induced tumorigenesis, we developed MMTV-
miR489 transgenic mice that specifically overexpress miR-489 in mammary 
epithelial cells.  Using this novel mouse model, we determined the function of miR-
489 in progenitor cell regulation. The data show that miR-489 overexpression 
delayed mammary gland development at early ages and impeded mammary tumor 
initiation, progression, and metastasis by regulating progenitor cells in a MMTV-
Her2 model of breast cancer. 
4.2 RESULTS 
4.2.1 DEMONSTRATION OF ENDOGENOUS MIR-489 EXPRESSION IN 
DIFFERENT TYPES OF MAMMARY EPITHELIAL CELLS AND DIFFERENT 
REGION OF MAMMARY GLAND  
To investigate the role of miR-489 in mammary gland development, its 
expression was determined in different cell populations of the mammary gland. 
Previously miR-489 was identified as differentially express in various populations 
of skeletal muscle with high miR-489 expression in quiescent satellite cells and 
dramatically lower levels upon entering actively dividing state of stem cells(Cheung 
et al., 2012). By using florescent-activated cell sorting (FACS), purified Lin- 
mammary epithelial cells from 6-week (wk) old FVB mice were separated into four 
subpopulations: stem- like cells (CD49fhighCD24med) (MRU), myoepithelial cells 
(CD49flowCD24low) (Myo), luminal progenitor cells (CD49fmedCD24high) (Ma-CFC) 
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and luminal cells (CD49flowCD24high) (Lum)(Stingl, 2009; Stingl et al., 2006) (Figure 
4.1 A). miR-489 expression was assayed on each of these populations by qRT-
PCR. Significantly higher expression of miR-489 was observed in stem like cells 
(MRU) compared to Luminal cells, Ma-CFC and myoepithelial cells (MRU vs Lum 
p=0.0012, MRU vs Myo p=0.0011, MRU vs Ma-CFC p=0.0017) (Figure 4.2.1 B). 
miR-489 expression was significantly reduced in progenitor cells (Ma-CFC 
population) (Lum vs Ma-CFC p<0.0001, Myo vs Ma-CFC p=0.0396).  This result is 
consistent with previous in vitro study that showed reduced miR-489 expression in 
















Figure 4.1: miR-489 expression in different sub population of mammary 
epithelial cells (A) Representative FACS profile for mouse mammary epithelial 
cells after eliminating hematopoit stained with CD24-PE and CD49f-FITC (B) 
Luminal, Ma-CFC, MRU and myoepithelial subpopulaitons were collected and 
assayed for expression of miR-489. (n=3 biological replicate, Lum vs MRU 
p=0.0012, Lum vs Ma-CFC p<0.0001, Myo vs MRU p=0.0011, MRU vs Ma-CFC 
p=0.0017, Myo vs Ma-CFC p=0.0396). 
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population(Greene, Gunaratne, Hammond, & Rosen, 2010). Together, these data 
suggest that miR-489 may be involve in regulation of stem-progenitor axis. It has 
been demonstrated that embryonically derived long label retaining cells, which 
represent quiescent mammary stem cells are restricted to the primary ducts near 
the nipple region(Boras-Granic, Dann, & Wysolmerski, 2014). Another study 
demonstrated Lgr5+ mammary epithelial cells, which reside in nipple areas, 
represent quiescent stem cells(Plaks et al., 2013). To determine whether miR-489 
expression varies in different part of mammary gland, RNA was collected from 
different fractions of inguinal mammary gland of 6-week-old mice as demonstrated 
in Figure 4.2 A. The results demonstrate that miR-489 is highly abundant in nipple 
area compared to empty fat pad and terminal end bud (TEB) enriched region 
(Frac1 vs Frac4 p=0.0004, Frac2 vs Frac4 p=0.0034) (Figure 4.2 B, C). Since the 
TEB region is enriched with active stem cells and progenitor cells, this experiment 
suggests miR-489 may be expressed at higher levels in quiescent mammary stem 
cells. However, further experiments are warranted to confirm this preliminary 
observation. Observing miR-489 expression in subset of BCL11 or Lgr5+Tspan8hi 
mammary stem cell populations, which is characterized as quiescent stem cells, 
will be interesting(Cai et al., 2017; Fu et al., 2017). Interestingly Lgr5+Tspan8hi 
population is mostly present in the nipple area, which has high level of miR-489 
expression. To gather, our data represent high miR-489 expression in stem cell 
compare to rest mammary epithelial cells. Also, low amount of miR-489 is present 
in progenitor cells which are highly dividing cells. Moreover, our mammary gland 
fractionation data represent high miR-489 expression in nipple area compare to 
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other fraction, which is also enrich with quiescence stem cells. Overall these 
results indicate possibility of miR-489 having role in stem cell regulation.  
 
 
4.2.2 DIFFERENTIAL EXPRESSION OF MIR-489 IN DIFFERENT STAGES OF 
MAMMARY GLAND DEVELOPMENT  
Mammary gland development occurs through distinctive stages throughout 
embryonic and pubertal development and reproductive life. At each stage different 
signals and different genes are required to induce changes in both the epithelium 
and surrounding stroma. Whole mammary gland development cycle is 
demonstrated in Figure 4.3. In the first few weeks after birth, growth of the 
mammary tree is steady with body growth. Terminal end bud (TEB) which are club-
shaped structures comprising an outer layer of cap cells and multilayered inner 
Figure 4.2: Demonstration of miR-489 expression in different fraction of 
mammary gland. A. Different fractions of the mammary gland has been collected 
from 6-week-old FVB female as demonstrated B. RNA was isolated from each 
fraction and examined for expression of miR-489 (n=3, Frac1 vs Frac4 p=0.0004, 
Frac2 vs Frac4 p=0.0034, Frac3 vs Frac4 p=0.0481). C. Representative RT-PCR 
gel image showing miR-489 expression in different fraction of mammary gland 
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core of cells called body cells, appear at the tips of the ducts and start to invade 
the fat pad. Once mammary tree structure feels mammary fat pad, growth will be 
ceased. During pregnancy period again, mammary gland will produce alveolar 
structure responsible for milk production. These structures will grow continuously 
during pregnancy period. During lactation period these structures will provide milk 










To find out whether miR-489 is differentially expressed in a temporal 
manner, RNA was isolated at different stages of mammary gland development 
including 3.5-wks, 7-wks, 14-wks, day-16 of pregnancy, day-9 of lactation, and 
Figure 4.3: Demonstration of different stages of mouse mammary gland 
development. Schematic stages of mammary gland development in the mouse 
from pre-puberty through to pregnancy, lactation and involution. LN indicates 
lymph node and TEB indicates terminal end bud. This figure has been adapted 
from (Watson & Khaled, 2008) 
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involution days-1, 3 and 5. Previously, it has been found miR-424(322)/503 cluster 
involved in involution process and their expression is upregulated during involution 
process(Llobet-Navas et al., 2014). Also, it has been found miR-30b involves in 











To confirm, RNA is isolated from correct phase, we first measured 
expression of miR-322-5p, miR-322-3p and miR-30b-5p in 7-week-old, lactation 
day 9, involution day 1, 3 and 5 (Figure 4.4 A, B, C). Consistence with previous 
observation, we also observed both miR-322-5p and miR-322-3p upregulated 
during involution day 3 (Figure 4.4 A, B). We observed upregulation of miR-30b as 
Figure 4.4: miRNAs expression during different stages of mammary gland 
development A, B, C. qRT-PCR data demonstrating miR-322-5p, miR-322-3p 
and miR-30b-5p expression during different stages of mammary gland. D. RT-
PCR data demonstrating miR-489 expression during different stages of mammary 
gland 
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well during lactation period (Figure 4.4 C). The RT-PCR results clearly 
demonstrated that miR-489 expression is gradually lost during pregnancy to 
involution day-3 (Figure 4.4 A). Since pregnancy- activated alveolar progenitor 
cells are abundant during pregnancy time and miR-489 is least express in 
progenitor cells(Tiede, Owens, Li, DeCoste, & Kang, 2009). These data suggest 
miR-489 expression is higher in mammary stem cells and least in progenitor cells. 
4.2.3 GENERATION AND CHARACTERIZATION OF MMTV-MIR-489 
TRANSGENIC MICE 
To investigate the role of miR-489 in mammary gland development and 
tumorigenesis, MMTV-miR-489 mice were generated which only overexpress miR-
489 in mammary epithelium (Figure 4.5 A). qRT-PCR data indicate significant up 
regulation of miR-489 in mammary epithelial cells of MMTV-miR-489 mice. (Figure 
4.5 B) (p<0.0001). DEK has been previously shown to be direct target of miR-489 
in muscle tissue(Cheung et al., 2012). Furthermore, SHP2 has also been identified 
as a direct target of miR-489in a variety of cells(Kikkawa et al., 2010; Patel et al., 
2016).  To test this in mammary tissue, miR-489-3p was transfected into mouse 
mammary epithelial cells C127 and 4T1. A significant down regulation of DEK and 
SHP2 was observed (Figure 4.5 C). To determine if this was extended to the mice, 
immunoblotting for DEK and SHP2 expression was performed with protein isolated 
from 6wk mouse mammary epithelial cells from FVB and MMTV-miR489 mice. 
Significant down regulation in DEK and SHP2 expression in MMTV-miR-489 mice 
were observed (Figure 4.5 D). Pups were generated by crossing FVB male and 
MMTV-miR-489 female. There was no significant defect on litter size and weight 
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(Figure 4.5 E). These data indicate that there is no defect on milk production by 














Figure 4.5: Generation of transgenic mammary tissue specific 
overexpression of miR-489 mouse model A. Schematic diagram of MMTV-
miR-489 transgenic mouse generation. B. RNA was isolated from mammary 
epithelial cells from FVB and MMTV-miR-489 mice and miR-489 expression was 
examined by qRT-PCR (n=9, p<0.0001) C. DEK and SHP2 were analyzed by 
Western blotting from protein lysate isolated from 4T1 and C127 cells transfected 
with Scr and mmu-miR-489 mimic for 72 hr. Western blot has been performed in 
three biological replicates. D. Western blot analysis was performed on protein 
lysate isolated from mammary epithelial cells from FVB and MMTV-miR-489 mice 
and analyzed for Dek, Shp2 and beta-actin. Western blot has been performed on 
three biological replicates. (n=2) E. Body weight of pups from FVB female and 
MMTV-miR-489 female were compared at day 7, 14 and 21. Student t test was 
used (n>7) 
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Together these data demonstrate that miR-489 expression is higher in 
mammary epithelial cells of MMTV-miR-489 mice and down regulates validated 
targets in mammary epithelial cells. 







Figure 4.6: Mammary Gland whole mount analysis between FVB and MMTV-
miR-489 mice A. Whole-mount carmine staining of mammary glands from 4-week, 
6-week, 8-week old virgin mice and involution day 4 stage. Representative images 
from a sister pair are shown. B, C. Distance of TEB from lymph node and Number 
of Terminal End Bud were measured for analysis purpose (n=9, for number of TEBs 
p<0.0001 and for distance p<0.0001). 
85 
It became critical to determine how these molecular changes impacted on 
mammary gland development. To check whether miR-489 overexpression affect 
mammary gland development, we first performed whole mount from inguinal 
mammary gland by carmine staining collected from FVB and MMTV-miR-489 mice 
at 4-wk, 6-wk, 8-wk and involution day-4 (ID4). Whole mount staining of the 
mammary gland revealed a significant delay in ductal growth and terminal end bud  
 
formation at 4- wks and 6-wks between FVB and MMTV-miR-489 female mice 
(Figure 4.6 A, B) (number of TEBs p<0.0001 and p<0.0001). However, miR-489 
overexpressing mammary gland captured growth equivalent to FVB at 8 weeks. 
We also examined formalin fixed mammary gland by Hematoxylin/eosin (H&E) 
 
Figure 4.7: Pathological Examination of mammary gland by H and E staining 
from 6-week-old FVB and MMTV-miR-489 mice. 
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Figure 4.8: Demonstration of proliferating cells by staining with Ki-
67 in mammary gland of 6-week-old FVB and MMTV-miR-489 mice A. 
Representative of Ki-67 staining demonstrated in TEB and duct of 6-week-
old mammary gland C. Histogram representing percent Ki-67 positive cells 
in TEB and Duct. Total 3 Duct and TEB were counted from each mouse. 




















TEB has high number of proliferative cells during pubertal period. To check 
whether miR-489 overexpression is affecting proliferative cells in mammary gland 
we performed immunohistochemistry to check Ki-67 positive cells. A less number 
Figure 4.9: Pathological Examination of mammary gland during involution 
stage from FVB and MMTV-miR-489 mice A. Hematoxylin and eosin (H&E) 
stained representative image of mouse mammary gland from involution day 2 and 
involution day 4 mice. B. Histogram representing number of cleaved caspase 3. 
positive cells in field.  
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of Ki-67 positive cells present in TEB and ducts of miR-489 mice suggests that 
miR-489 overexpression affected actively proliferating cells (Figure 4.8) (TEB 
p<0.0001, Duct p=0.0441). Therefore, there is significant growth difference 
between FVB and transgenic mice. 
Similarly, mammary glands from ID4 suggested the involution process was 
observed to occur a little faster in MMTV-miR-489 mice as compared to FVB 
(Figure 4.6 A). However, pathological examination revealed no difference in acini 
between FVB and miR-489 mice at ID2 and ID4 (Figure 4.9 A). Also, we performed 
immunohistochemistry to observe cleaved caspase 3 (Figure 4.9 B). No significant 
difference was detected in cleaved caspase-3 positive cells in miR-489 mammary 
gland at ID4 (Figure 4.9 C). Further study is warranted to confirm the role of miR-
489 in the involution process. Overall, these results suggest miR-489 
overexpression inhibited mammary gland development by reducing highly 
proliferative cells in early age.  
4.2.5 EFFECT OF MIR-489 OVEREXPRESSION ON DIFFERENT MAMMARY 
EPITHELIAL CELLS 
miR-489 overexpression has any effect on mammary epithelial cell 
differentiation hierarchy was examined. Lin- mammary epithelial cells were 
obtained from 6wk FVB and miR-489 mice. MECs were stained with CD49f and 
CD24 antibodies to distinguish different population of mammary gland. FACS 
analysis demonstrates a significant reduction in Ma-CFC population in MMTV-miR-
489 mice (p=0.0016; Figure 4.10 A). Similarly, we observed significant reduction 
of CD49fhiCD24hi population upon overexpression of miR-489 in C127 cells 
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(p=0.002; Figure 4.10 B). To validate this observation, a colony formation assay 






















Figure 4.10: Effect of miR-489 overexpression on progenitor cells. A. 
FACS analysis was performed to examine the luminal progenitor cell population 
(CD49fmedCD24hi) in mammary epithelial cells from 6-week-old FVB and MMTV-
miR489 transgenic mice (n=3). P=0.0016 (unpaired student t test) B. C127 cells 
were transfected with Scr and miR-489 mimic for 72hr and cells were stained 
with CD49f and CD24 and analyzed C. Colony formation assay was performed 
from mammary epithelial cells from 6-week-old FVB and MMTV-miR489 
transgenic mice (n=3). P=0.0038 (unpaired student t test). D. Mammary 
epithelial cells were isolated from 24-week-old Her2 and Her2-miR489 mice and 
stained with CD49f-FITC and CD24-PE and analyzed for Ma-CFC population 
(n=3). P=0.0015 (unpaired student t test). 
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These data demonstrate a significant decrease in the number of colonies 
formed using isolated MECs from miR-489 mice compared to FVB mice 
(p=0.0038; Figure 4.2.10 C). Committed progenitor cells are a major target for 
malignant transformation. In our previous study, we observed an increase in 
progenitor population in MMTV-Neu mice before tumor onset(Lo et al., 2012). To 
check whether miR-489 restoration has any effect on Her2 induced progenitor 
cells, Lin- mammary epithelial cells were analyzed from pre-neoplastic mammary 
glands from Her2 and Her2/miR489 mice. Significant reduction in 
CD49fmid/CD24high population was observed in Her2/miR489 mice compared to 
Her2 mice (p=0.0015; Figure 4.10 D). All these results suggest miR-489 
restoration might target progenitor cells, which are the major target for malignant 
transformation by Her2 induced tumorigenesis. These studies have been 
performed on nulliparous mice. Further study is warranted to observe parity-
identified mammary epithelial cells (PI-MEC) which has been also suggested as a 
target population of Her2/neu-driven tumorigenesis(Jeselsohn et al., 2010; 
Yallowitz et al., 2014). Although it has been found that PI-MEC are part of luminal 
progenitor population(Chang et al., 2014). 
4.2.6 DEMONSTRATION OF EFFECT OF MIR-489 OVEREXPRESSION ON 
HER2 INDUCED TUMOR INITIATION, MULTIPLICITY AND PROGRESSION 
It has been demonstrated that miR-489 expression is lost during tumor 
progression. To study the role of miR-489 in mammary tumorigenesis in vivo, 
MMTV-Her2-miR-489 mice were generated by intercrossing MMTV-Her2 mice 
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These mice overexpress both Her2 and miR-489 in mammary epithelial 
cells. All mice in this tumor study were nulliparous. MMTV-Her2 transgenic mice 
have been shown on FVB/N background to develop palpable mammary tumors 
around 6 months of age and eventually show 100% tumor penetrance. Mammary 
tumor successfully overexpresses miR-489 compared to Her2 tumor (Figure 4.11 
A) (p=0.0016). In MMTV-Her2 mice, palpable mammary tumors appeared as early 
as 167 days of age with a median onset at 259 days; by 400 days of age all females 
had palpable tumors as expected (n=34; Figure 4.11 B). In contrast, MMTV-Her2-
miR489 mice developed palpable tumors starting at 203 days, with 50% of the 
mice showing tumors by 378 days and 13% mice didn’t develop any tumor until 
570 days (n=19; Figure 4.11 B). Thus, overexpression of miR-489 significantly 
Figure 4.11: Demonstration of tumor initiation and multiplicity in MMTV-
Her2 and MMTV-Her2/miR-489 mice. A. qRT-PCR data demonstrating miR-
489 expression in mammary tumor from MMTV-Her2 and MMTV-Her2/miR-489 
(P=0.0016) B. Kaplan-Meier Curves of mammary tumor free survival of virgin 
MMTV-Her2 (n=15) and MMTV-Her2-miR489 mice (n=20). The p value was 
calculated using the long rank-rank test (p<0.0004) C. Mammary tumor 
multiplicity between MMTV-Her2 (n=17) and MMTV-Her2-miR489 (n=18) mice 
(P=0.0008) 
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delayed onset of Her2 induced mammary tumors (P<0.0001). Consistent with this 
observation, upon sacrificing mice at 8-wk after first palpation of the tumor, we 
found significantly reduced tumor multiplicity in mice overexpressing miR-489 
















Tumor size was measured for the first tumor in each mouse every 7 days 
after onset (Figure 4.12 A). Data showed that the tumors of double transgenic mice 
were significantly smaller than Her2 mice (Figure 4.12 B) (P=0.0086). miR-489 
expression restoration also inhibited tumor growth of HCC1954 and MDA-MB-231 
Figure 4.12: Demonstration of tumor progression in MMTV-Her2 and 
MMTV-Her2/miR-489 mice. A. Tumor growth was monitored every 7 days. 
Comparison of tumor volume between Her2 and Her2/miR489 each week. 
Tumor volumes were measured at indicated weeks. B. Final tumor sizes of both 
group were compared (P=0.0086) C. Proliferation rate was assessed by Ki-67 
immunostaining comparing tumors from MMTV-Her2 (n=10) and MMTV-Her2-
miR489 (n=15). At least 500 cells have been counted per mammary tumor. 
(p<0.0001) 
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in xenograft model as well(X. Chen et al., 2016; Patel et al., 2016). Tumor sections 
from both groups were examined for Ki-67 positive cells, a marker for proliferation. 
Significantly less number of Ki-67 positive cells were observed in double 
transgenic mice (P=0.0004; Figure 4.12 C). These data partially explain the 
significant difference in tumor size between the two groups. 
4.2.7 EFFECT OF MIR-489 OVEREXPRESSION ON HER2 INDUCED LUNG 
METASTASIS AND CANCER STEM CELLS 
Furthermore, upon microscopic examination of multiple organs, we showed 
43% of MMTV-Her2 and MMTV-Her2-miR-489 mice harbored micro-metastasis in 
the lung. However, double transgenic mice had three times less metastatic foci 
compared to Her2 transgenic mice (p=0.0035; Figure 4.13 A, B). In a previous 
report it was demonstrated that miR-489 was significantly down regulated in 
derivatives of MDA-MB-231 cells, which are highly metastatic to lung and bone. 
Upon restoring miR-489 expression, decreased lung colonization was observed at 
initial stages, but in later stages no significant difference was detected(Tavazoie 
et al., 2008). A Partial explanation for the contrast in this observation could be that 
both experiments were performed in different model systems. Further study is 
warranted to determine the underlying mechanism of how miR-489 regulates 
metastasis of Her2 positive tumor cells to the lung. Previously, we established that 
CD49fhiCD61hi cells exhibit stem- like traits of self-renewal and regenerating 
heterogeneity in Her2 induced mammary tumor(Lo et al.,2012). 




















We found a significant reduction in CD49fhiCD61hi population by miR-489 
expression restoration (n=8, p=0.03377; Figure 4.13 C). Overall, these results 
indicate miR-489 overexpression didn’t affect lung metastasis ratio in mice 
however it reduced lung metastatic foci. Also, miR-489 overexpression affected 
Her2 induced cancer stem cell population as indicated by figure 4.13 C.          
Figure 4.13: Demonstration of Lung metastasis and population of tumor 
initiating cells in tumor of MMTV-Her2 and MMTV-Her2/miR-489 mice. A. H 
and E staining of lungs of MMTV-Her2 and MMTV-Her2-miR489 mice. Images 
were taken at 4x and 10x magnification B. Quantitation of the number of metastatic 
foci in the lungs of MTTV-Her2 and MMTV-Her2-miR489 mice after 8-week post 
tumor onset (n=17) (p=0.0035). C. FACS analysis of the putative CSC cells 
(CD49fhiCD61hi population) in the first mammary tumor of each animal (n=8). 
P=0.0337 (unpaired student t test) 
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4.2.8 EFFECT OF MIR-489 OVEREXPRESSION ON HER2 SIGNALING 
PATHWAY AND PROLIFERATIVE CELLS IN HER2 INDUCED MAMMARY TUMOR 
To further dissect the underlying mechanism, protein samples isolated from 
mammary tumors from both groups were analyzed by immunoblotting. There was 
a significant reduction in SHP2, DEK, pAKT and pERK in Her2/miR489 mice 
compared to Her2 mice (Figure 4.14 A, B, C). We found variable expression of 
miR-489, Shp2 and Dek in mammary tumor. To find is there any correlation 
between miR-489 expression and its target in mammary tumor, we performed 
linear regression analysis between miR-489 expression and quantified Shp2 and 
Dek protein expression based on western blot. Our linear regression analysis data 
suggest negative correlation between miR-489 expression and Shp2 and Dek 
protein (Figure 4.14 D, E). It has previously been demonstrated that DEK plays an 
oncogenic role through the paracrine Wnt signaling pathway in Ron receptor 
positive breast cancers(Privette Vinnedge et al., 2015). DEK down regulation may 
also have a role in Her2 mediated tumorigenesis. To address this issue Kaplan-
Meier plot analyses were performed and patients with high DEK expression in their 
breast tumors, had worse overall survival as compared to patients with low DEK 
expression (Figure 4.15). It has been shown that SHP2 positively regulates Her2 
induced transformation and proliferation by dephosphorylating an 
autophosphorylation site which serve as docking site for Ras-GTPase activating 
protein. This action of SHP2 increases the intensity and duration of GTP-Ras 



















Figure 4.14: Demonstration of Her2 signaling pathway in mammary 
tumor A. Immunoblotting of DEK, SHP2, Phospho-Akt, Akt, Phospho-ERK 
and ERK in mammary tumors of Her2 and Her2/miR489 mice; n=5 mice per 
group. B. quantification of SHP2 protein levels in mammary tumors of Her2 
and Her2/miR489 mice. C. quantification of DEK protein levels in mammary 
tumors of Her2 and Her2/miR489 mice. All results were confirmed in at least 
three independent experiments, and all quantitative data are presented as 
mean ± SD or SEM as indicated. D. Correlation of miR-489 expression and 
Shp2 protein expression in mammary tumor from MMTV-Her2/miR-489 
mice. E. Correlation of miR-489 expression and Dek protein expression in 














Kaplan-Meier plotter analyses demonstrate that HER2 positive breast 
cancer patients with low miR-489 expression have worse overall survival 
compared to patients with high miR-489 expression (P=0.00016, Figure 4.15). 
4.2.9 DEMONSTRATION OF MIR-489 EXPRESSION IN MAMMARY TUMOR AND 
ADJACENT MAMMARY GLAND FROM MMTV-HER2/MIR-489 MICE  
Previously, by using breast cancer patient samples we have demonstrated 
miR-489 expression lost in tumor cells compare to adjacent mammary gland. Also, 
previously we have demonstrated miR-489 expression regulation via HER2 
overexpression. But, we failed to demonstrate whether HER2 regulating miR-489 
via traditional transcriptional level or via long non- coding RNA. However, we 
observed miR-489 expression correlation with CALCR gene expression in patient 
sample. miR-489 and CALCR share same transcription start site. But, we further 
4.15: Demonstration of clinical correlation A. Kaplan-Meier 
curves of overall survival of Her2 positive breast cancer patients 
stratified by miR-489 (n=608 patients) B. Kaplan-Meier curves 
of overall survival of breast cancer patients for DEK (n=1117 
patients). P values were calculated from a log-rank test. Data 
were obtained from http://kmplot.com/analysis/ 
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want to dissect whether HER2 regulates miR-489 expression via any other 
nontraditional alternative way. To check this possibility, we analyzed miR-489-3p, 
miR-489-5p and pre-miR-489 expression by using qRT-PCR in mammary tumor 
and adjacent mammary gland from MMTV-Her2/miR-489 mice (Figure 4.16). We 
observed seven-fold down regulation of miR-489-3p expression in mammary 
tumor compare to adjacent mammary gland (Figure 4.16 A). We observed pre-
miR-489 whose expression didn’t change significantly (Figure 4.16 B). Also, we 
observed two-fold down regulation of miR-489-5p in tumor sample (Figure 4.16 C). 
These observations suggest non-traditional way of regulation of miR-489 in Her2 
overexpressing tumor. Since this miR-489 overexpression is governed by MMTV 
promoter not CALCR gene promoter. Moreover, expression of pre-miR-489 and 
miR-489-5p didn’t change significantly. We have cloned pre-miR-489 under MMTV 
promoter so it is expected whole pre-miR-489 should be upregulated in these mice. 
Also, miR-489-5p should be upregulated since it is product of pre-miR-489. So, in 
these mice miR-489 overexpression is regulated via MMTV promoter not Calcr 
promoter. There is a possibility miR-489 might be regulated by Her2 via long non-
coding RNA. Long non-coding RNAs act as sponge and they regulate miRNA 
expression. There should be long non- coding RNA which expression regulated by 
Her2 overexpression. Further study is warranted to find specific long non-coding 















4.3 SUMMARY AND DISCUSSION 
 A growing number of reports have suggested the role of miRNA in breast 
cancer based on in vitro and xenograft based models. Recently, few miRNA 
knockout models have been generated to study the roles in autochthonous 
mammary tumors(Kim et al., 2016; Rodriguez-Barrueco et al., 2017). In this study, 
we demonstrate for the first time the role of miRNA-489 in the mammary stem cell 
hierarchy and Her2 induced tumorigenesis by using a mammary specific 
overexpression model in MMTV-Her2 mice. Overexpression of miR-489 reduced 
Figure 4.16: miR-489 expression analysis in mammary tumor and adjacent 
mammary gland from MMTV-Her2/miR-489 mice A, B, C. qRT-PCR 
demonstrating miR-489-3p, pre miR-489 and miR-489-5p expression in 
mammary gland and mammary tumor 
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progenitor cells, which are the major target population for malignant transformation 













This can be partially responsible for miR-489 overexpression mediated 
delay in mammary tumor onset. Further, miR-489 overexpression reduced 
expression of DEK, SHP2 and Her2 signaling pathways, thus decreasing cell 
proliferation and inhibiting tumor progression in Her2 induced tumorigenesis model 
(Figure 4.17). Our study indicates miR-489 is highly expressed in stem cells and 
significantly reduced in progenitor cells. Furthermore, miR-489 is at very low 
expression in TEB which harbors actively dividing stem cells thus supporting idea 
that miR-489 is highly expressed only in quiescent stem cells. Accordingly, we 
propose a functional model in which miR-489 may involve in regulation of the 
Figure 4.17: Model demonstrating role of miR-489 in Her2 mediated 
tumorigenesis. 
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quiescent state of stem cells, thereby regulating progenitor cell population. Further 
studies will be required to validate this hypothesis.  Based on our data, we 
proposed model where miR-489 overexpression inhibit Dek and Shp2 and 
attenuate mammary gland development at early age. Moreover, miR-489 
overexpression has inhibited progenitor cell population which are target population 
of Her2 mediated tumorigenesis in MMTV-Her2 mouse model which mimic human 
HER2 positive breast cancer. Also, miR-489 overexpression inhibited Her2 
mediated tumor initiation, progression and lung metastasis by attenuating Her2 
signaling pathway (Figure 4.17). It is very interesting here miR-489 overexpression 
is not inhibiting Her2 but inhibiting Her2 signaling pathway. It is raising important 














MATERIALS AND METHODS 
Cell culture 
MCF7 vect and MCF7 HER2 cell lines were kindly provided by Dr. Rachel Schiff 
(Baylor College of Medicine) and were grown in DMEM supplemented with 10% 
FBS and 5 μg/ml insulin. Other breast cancer cell lines AU-565, BT-474, 
HCC1954, T47D, ZR-75-1, HCC1569, 4T1 and ZR-75-3 were purchased from 
ATCC and cultured in RPMI-1640 (Corning, Manassas, VA) containing 10% FBS. 
All cells were cultured at 37°C in a humidified incubator containing 5% CO2. MDA-
MB-468, MDA-MB -231, MDA-MB -435, SK-BR-3, BT-549, HS578T and MDA-MB 
-453 were purchased from ATCC and cultured in DMEM (4.5 g/L glucose, 110 mg 
sodium pyruvate/L and L-glutamine) (Mediatech, Inc. Corning, Manassas, VA) 
containing 10% FBS. All cells were cultured at 37°C in a humidified incubator 
containing 5% CO2.  
Colony formation assay 
We transfected mimic-miR-489 and inhibitor-miR-489 in MCF7 and MD-MBA-231 
cells and incubated cells for 24 hr. After incubation, we collected all cells. For MCF-
7 10000cells/well and for MD-MBA-231 4000cell/well were plated in 6 well plates 
in triplicates in DMEM media containing 10% Fetal Bovine Serum (FBS).  After one 
week of incubation in 5% CO2, cells were washed with 1x phosphate-buffered 
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saline (PBS) and fixed using 100% methanol. Once fixed, cells were washed again 
with 1x PBS and stained with 0.5% crystal violet. All the visible colonies were 
photographed and manually counted, and the average with standard error of mean 
was plotted using graphpad prism software. 
MTT Assay 
Cell viability was examined by the 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded at a density of 
4,000 cells/well in triplicate in 96-well plates. Cells transfected with either 
0.32µl/well scrambled, miR-489 mimics, or miR-489 Inhibitor by using 0.32µl/well 
Lipofectamine RNAi and incubated at 37 °C for 72 hr. Cells were seeded at a 
density of 13,000 cells/well in triplicate in 24-well plates. Cells transfected with 
either 1µl/well scrambled, miR-489 mimics, or miR-489 Inhibitor by using 1µl/well 
Lipofectamine RNAi and incubated at 37 °C for 72 hr.  MTT assay was performed 
according to mention above. At the end of the incubation media was removed and 
formazan precipitates were dissolved by adding 200 µl of DMSO in each well. OD 
values were measured at both 570 and 630 nm and final values were calculated 
by subtracting OD630 from OD570.  These values for each time point were used to 
plot the growth curve for each clone using graphpad prism.   
Cell Cycle analysis 
Supernatant was collected to observe apoptotic cells. Cells were harvested using 
Accutase, washed with cold PBS and fixed with 70% cold ethanol. Cell pellets were 
then treated with 100 μg/ml RNase A for 15 min at 37°C and stained using 50 
104 
μg/ml Propidium Iodide (PI) for 30 min on ice. Samples were analyzed using BD 
Accuri flow cytometer.  
Luciferase assay 
MCF-7 vect and HER2 cells were seeded at 1.25 x 105 cells/well 24 h prior to the 
transfection in a 24 well plate. Cells were transfected with 500 ng of pGL3 promoter 
vector containing 3’UTR of HER2 or mutated 3’UTR, 20 ng of pRL-CMV (Renilla 
luciferase vector-Promega) and 500 ng of miR-489 pcDNA 3.1 vector or empty 
pcDNA 3.1 vector. After 48 h post transfection, luciferase activity were measured 
using Dual-luciferase reporter assay system (Promega Cat# E1980) as per 
manufacturer’s instructions and normalized to the levels of Renilla luciferase 
activity.  
Plasmid constructs  
A 650 bp long 3’ UTR of human HER2was amplified from genomic DNA and cloned 
into the pGL3-promoter vector at the same Xba I and BamH I sites. For the 
mutation analysis putative miR-489 target site within 3’UTR of HER2 was mutated 
by Phusion site directed mutagenesis kit (Thermofisher Cat# F-541). All 
sequences were verified by direct sequencing of the plasmids.  
Stable Cell line generation  
293T cells were transfected with 3µg of SHP2 (Zhang et al. addgene #8329)/HER2 
plasmid (provided through the courtesy of Emily Wang at the Institute of City of 
Hope), 3µg of VSVG plasmid and 2.5µg of ECO plasmid using 17µl of 
Lipofectamine2000 for 48 hrs. After 48 hrs, supernatants were collected and spin 
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down at 10,000 RPM at 4 °C to discard any cell debris. MDA-MB -231 cells were 
infected with SHP2 and HER2 lentivirus for 48 hrs. Infected cells must be 
puromycin resistant and therefore cells were treated with puromycin for one week. 
1µg CDK1 (Van et al. addgene#1886) plasmid was transfected using 2 µl 
of Lipofectamine2000 for 48hrs. After 48hrs cells were selected with 2000 g/mL 
G418 Sulfate (Mediatech, Inc. Corning, Manassas, VA).   
3µg pCMV FOXM1 (Kind gift from Dr. Suyun Huang, MD Anderson) and 
0.6µg pCMV plasmids were transfected using 7.2µl of Lipofectamine2000 for 
48hrs. After 48hrs cells were selected with 2000µg/ml G418 Sulfate (Mediatech, 
Inc. Corning, Manassas, VA). 
Preparation of miR-489-delivering nanoparticle 
Liposomes were prepared as described elsewhere with some modifications(S. D. 
Li, Chono, & Huang, 2008; S. D. Li & Huang, 2006). Briefly small unilamellar 
liposomes consisting of DOTAP and cholesterol were prepared by thin film 
hydration method. The film was hydrated with nuclease free water and sonicated 
in a bath type sonicator for 5 min followed by extrusion through 200 and 50 nm 
membrane filters. The total lipid concentration of the liposomes was fixed at 28.6 





Clinical tissues and Fluorescent in situ hybridization (FISH) 
Human breast cancer tissue samples were obtained through the South Carolina 
Tissue Bank with approval from the Institutional Review Board at the University of 
South Carolina. Tissue samples were randomly collected from patients who were 
diagnosed with invasive breast ductal carcinoma between 2003 and 2007. The 
tissue samples from breast cancer patients who underwent surgery in 2008 were 
provided by the Chonnam National University Hwasun Hospital National Biobank 
of Korea, a member of the National Biobank of Korea, which is supported by the 
Ministry of Health, Welfare and Family Affairs.  
Tissue sections were dewaxed and rehydrated with phosphate buffered 
saline (PBS) and fixed using 4% paraformaldehyde (PFA). Next, tissue sections 
were treated with proteinase K (50μg/μl, life technology) for 15 min at 37°C. 
Acetylation of tissue sections were performed with 0.1M triethanolamine/0.25% 
acetic anhydride for 5 min. Sections were washed once with PBS. Before 
proceeding with hybridization step, Hybridization buffer was prepared by mixing 
250 μl of formamide, 250 μl of 20x SSC, 50×Denhard’t solution (life technology), 
12.5 μl of t-RNA (Roche), 2.5 μl of Herring Sperm DNA (Promega D1815), 0.02 
gm of blocking reagent (Roche) and 30 μl of RVC (Fisher) in 1 ml. Sections were 
pre- hybridized with hybridization buffer for 2 h at room temperature.   
LNA-substituted DNA oligonucleotide probe for miR-489 was obtained from 
Exiqon (Cat#38599-01) labelled with digoxigenin at the 5’ terminus. Probes were 
denatured at 95°C for 5 min, then chilled on ice for 5 min. Total of 100 μl diluted 
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probe was added to cover tissue area. Slides were kept in the hybridization 
chamber and incubated in oven at 55°C overnight. Next day, sections were 
washed once with 5x SSC for 7 min and twice each with 1x SSC (7 min) and 0.2x 
SSC (7 min) at 57°C, followed by two 7 min washes with 0.2x SSC at room 
temperature and final wash with 1x PBS. Sections were blocked with blocking 
reagent (life technology: E-6604) for 1 hour at room temperature, followed by 
incubation with anti-DIG AP labelled primary antibodies for 1 h at room 
temperature (Roche: 11093274910). Sections were washed with 1x PBS for 5 min 
and developed for microscopic visualization using ELF-97 kit from Life technology. 
Xenograft experiments  
Five to six weeks old athymic female nude mice were purchased from Jackson 
Laboratories. All mice were handled and maintained under supervision of 
veterinarian in accordance with institutional guidelines and under a University of 
South Carolina Institutional Animal Care and Use Committee (IACUC) approved 
protocol. All mice were subcutaneously injected with 2 x 106  HCC1954 in both right 
and left flank of each mice (n=5/group). The mice tumors were palpated starting 
day 9 post injection. Tumor volumes were calculated by measuring length and 
width twice a week for 4 weeks. After 4 weeks of tumor palpation, all mice in the 
control group were photographed and tumors were extracted after euthanizing all 
animals. Tumor volumes of each tumor was calculated by modified ellipsoidal 
formula (1/2(lxw2)). Tumor volumes were plotted using graphpad prism software. 
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Similarly, for nano-particle delivery experiment five to six-week-old athymic nude 
female mice were subcutaneously injected with 2 million wt-HCC1954 cells. The 
day tumors start palpating, each mouse was given intratumoral injection of nano-
particle containing either scramble or mimic-miR-489 every 3 days for one month 
(25 μM/treatment). Tumor volumes were measured, calculated and plotted as 
mentioned above. 
Mouse Strains 
All mice experiments and breeding were performed with approval of the University 
of South Carolina IACUC. For sorting experiment, 6-week-old FVB mice were used 
for this experiment. For each experiment 4 sister mice were used. For rest of the 
stage female mice were kept with males. For Pregnancy day 16, female mice were 
kept with male and copulation was confirmed by plug visualization and males 
removed post coitum. For involution and lactation, pups were removed on day 9 of 
lactation and mammary glands were collected on day 1, 3 and 5 after the removal 
of pups. The full-length mouse pre miR-489 cDNA was amplified by PCR and 
inserted into a pMMTV vector (a kind gift from Dr. Jeffrey Rosen at Baylor College 
of Medicine) to generate the plasmid MMTV-miR-489. Pronuclear microinjection 
to generate transgenic mice was performed by the core facility at MUSC(Cho, 
Haruyama, & Kulkarni, 2009). Transgenic progeny was identified by southern blot 
analysis and PCR also was performed with genomic DNA isolated from tail biopsy. 
The following primer pairs were used to perform genotyping: F-
5’ACCAGGTCCTGTTGTAGGTTC3’ and R-5’TACTCTGAGTCCAAACCGGG3’. 
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Spontaneous Mammary Tumor Experiment 
MMTV-Neu mice were purchased from Jackson laboratory. MMTV-Neu mice were 
crossed with MMTV-miR489 mice to generate MMTV-Her2-miR489 double 
transgenic mice. For analysis of mammary tumor incidence, we monitored adult 
female mice starting at 4 months of age and once per week. We monitored the 
mice weekly and noted the time of tumor appearance, tumor size, the number of 
tumors and lung metastasis in each mouse. After detecting palpable tumor, tumor 
size was measured every week. Tumor free survival curves were evaluated using 
Kaplan-meier method and differences between the survival curves were evaluated 
by a log-rank test. Tumor volume of each primary tumor was calculated by modified 
ellipsoidal formula (1/2 (LxW2)). Tumor volumes were plotted using graph-pad 
prism software.  
Mammary Gland Digestion 
Thoracic and inguinal mammary glands were used. Glands were minced and 
digested for 4-6 h at 37°C in DMEM/F12 medium supplemented with 750U/ml 
Collagenase and 250U/ml hyaluronidase. After this step cells organoids were 
collected by centrifugation then subjected to ammonium chloride to lyse 
erythrocytes. After that cells were collected and subjected to separate trypsin 
(0.5%), dispase (5 mg/ml) and DNase treatment. Cells were passed through a 
40µM strainer and subjected for hematopoietic cell depletion. Mouse epithelial cell 
enrichment kits were obtained from Stem Cell Technologies (catalog#19758) and 
their protocol was followed. Cells were stained by anti- CD49f (2µl antibody for 
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1million cells) and anti-CD24 (1.5µl antibody for 1million cells) antibody for 30min 
on ice. CD49f was obtained from Bio-Legend (cat#313606) and anti-CD24 was 
obtained from BD bioscience (cat#553262). These stain cells were used for either 
cell analysis or cell sorting experiment. Cells were analyzed with BD Accuri C6 
flow cytometer for different mammary epithelial cell population. A total of 35,000 
events were collected for each sample. Different fractions were sorted by using BD 
FACS aria II sorter.  
Mammary Gland Whole Mount Analysis 
Dissected 4th inguinal mammary glands were spread on glass slides and exposed 
to kahle’s fixative overnight. Glands were stained overnight with carmine alum. 
Adipose was removed by exposure to xylene overnight. For whole mount analysis, 
a total of 9 pairs of sister mice were used. 
Ma-CFC Assay 
Mammary epithelial cells were seeded in plates for Ma-CFC colony formation 
assay as described previously(Shehata et al., 2012). Mammary tumors were 
harvested, minced and incubated in digestion media to generate single cell 
suspensions (described above) at 37°C for 2h. 
 
Real Time Cell Analysis Assay 
MDA-MB-231 cells were seeded in 1800 cells per well density. Cells were 
transfected with either scramble or mimic-miR-489 at 28nM concentration. Cells 




Total RNA was isolated either from cells or murine tissues using the RNeasy RNA 
isolation kit (Qiagen, Valencia, CA) or E.Z.N.A.® Total RNA Kit I (Omega BioTek, 
Norcross, GA) . cDNA was synthesized from the total RNA extract using iScript 
cDNA synthesis Kit (Bio-Rad, Hercules, CA). The kits were used following 
manufacturer’s instructions. RNA was isolated using Trizole reagent from 
mammary epithelial cells derived from 3.5, 7 and 14 weeks old nulliparous FVB 
mice. RT-PCR was performed as previously as previously described to quantitate 
miR-489 expression with U6 as an internal control(Patel et al., 2016). All statistical 
tests were performed by student t-test using prism (GraphPad software, Inc., San 
Diego, CA, USA). For qRT-PCR statistical analyses were performed on 2-CT 
values. All results were confirmed in at least three independent experiments, and 
all quantitative data are presented as mean ± SD or SEM as indicated. 
Microarray Analyses 
T47D cells were seeded in 6 well plate at 120000 cells per well density. Cells were 
transfected with either scramble or mimic-miR-489 for 72 hr. After 72 hr, RNA was 
isolated using Trizole.  
cDNA preparation for miRNA analysis 
Poly A tail was added to RNA by using Poly A polymerase enzyme. cDNA was 
prepared by using polydT adaptor. The universal R was used as reverse primer 
for miRNA detection by qRT-PCR. Here is sequence of poly dT adaptor: 
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN and 
Universal R: GCGAGCACAGAATTAATACGAC. 
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Analysis by Quantitative Real-Time PCR 
Quantitative Real-Time PCR (qRTPCR) was performed on cDNA samples using 
an Applied Biosystems 7300 Real Time PCR System (Thermo Fisher Scientific 
Inc., Waltham, MA) with SYBR green enzyme from quiagene. qRTPCR Primers 
for various genes were obtained from Integrated DNA Technologies (IDT, 
Coralville, IA). The primer sequences are as follows:  
mmu-miR-489-3p 5’-AATGACACCACATATATGGCAGC-3’  
U6 F-5’ GACGTGAGGCGACAAGATGG3’ 
      R-5’AAAGCCCTTCAGGATACCGC3’. 
RNU48 F-5’TGCGATGATGAGTGAAGTAGAGC3’ 
   R-5’ATACCCTGGTCAAAGCCAACA3’ 
Measurements were run in triplicate and transcription levels were 
determined relative to β-actin expression levels for gene and to RNU48 expression 
levels for miRNA.  
 
Western Blotting 
Protein extracts were obtained from whole cell lysates from breast cancer cell lines 
or mammary epithelial cells from mouse mammary gland. Isolation of protein in-
vitro was performed using M-PER (mammalian protein extraction reagent, 
Thermofisher, Grand Island, NY) with a protease inhibitor (Sigma, St. Louis, MO) 
following manufacturer’s instructions. Proteins were separated on 7% precast 
acrylamide gels, transferred to nitrocellulose blots, and probed with primary with 
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antibodies against HER2, p-HER2, Akt1, p-Akt1, ERK1/2, p-ERK1/2, SHP2, DEK, 
CDK1, FOXM1, CyclinE2, CyclinB1 and CyclinA2. Blots were incubated with 
primary antibodies overnight at 4ºC, washed with PBS/0.01% Tween-20, probed 
with HRP-conjugated secondary antibody (Bio-rad, Hercules, CA) for 1 hour at 
room temperature, washed, and visualized with ECL enhanced 
chemiluminescence kit (ThermoFisher Scientific Cat#). Blots were visualized using 
either the GE ImageQuant LAS 4000 (GE Healthcare Bio-Sciences, Pittsburgh, 
PA). As internal controls for equal loading, blots were re-probed with either Hrp-
conjugated Anti-β-actin (Santacruz Biotechnology, Santa Cruz, CA) or Anti-
GAPDH Rabbit pAb (Santa Cruz Biotechnology, Santa Cruz, CA) after stripping 
the blot with a mild stripping buffer. Western images were quantified using GE 
ImageQuant Software. All primary antibodies were obtained from cell signaling. 
DEK was purchased from protein technology.  
Histology  
Tumor-bearing mice were sacrificed and the liver, spleen, and cecum were excised 
and fixed in freshly prepared 4% paraformaldehyde in PBS, pH 7.2. Tissue blocks 
were embedded in paraffin, 5 μm sections obtained and then stained with 
hematoxylin and eosin (H&E) (VWR, West Chester, PA) for visual examination.  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed using 5 μM sections of xenografted 
tumor, spontaneous tumor and mammary gland fixed in Formalin overnight. 
Parraffin-embedded tissue sections on poly-L-lysine-coated slides were dewaxed 
in xylene (2 x 5 minutes) and rehydrated by washing in decreasing concentration 
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of ethanol: 2 x 3 minutes in 100 percent ethanol, 2 x 3 minutes 95 percent ethanol 
and 1 x 3 minutes 75 percent ethanol. Antigen reterival was carried out by 
incubating slides in preheated citrate buffer (95 °C, pH6) for 30 minutes. Sections 
were blocked with 3 percent peroxide for 10 minutes. Sections were blocked with 
0.1 percent BSA/PBS buffer for 1 hr at room temperature. Primary antibodies were 
obtained from Cell signaling, Ki-67 (Cat#9027), HER2 (Cat#2242), cleaved 
caspase 3 (Cat#9661) and phospho-p44/42 MAPK (Erk1/2) (Cat#9101). For, 
mouse tissue, Ki-67 was obtained from BD (Cat#550609). Antibody for SHP2 was 
obtained from protein tech (Cat#24570-1-AP). All antibody dilutions were used 
accordingly instruction. All primary antibody was incubated for overnight at 4 C. 
Unbound antibodies were removed by using 0.1 percent tween/PBC buffer three 
times. Sections were incubated with anti-rabbit or mouse biotinylated antibody. 
Signal was amplified by using avidin-biotin complex (ABC kit) from Vector 
Laboratories. Sections were developed using DAB from Vector Laboratories.  For 
Ki-67 positive cell counting in tumors, total 1000 cells were counted from each 
individual tumor. For Ki-67 positive cell counting in mammary gland, 3 independent 
ducts and TEBs were counted from each mammary gland tissue. Total of 5 pairs 
of sister mice were used. 
siRNA Knockckdown of Akt1 and SHC 
MCF7 Vector and HER2 cells were seeded at 80,000 cells per well density. Cells 
were transfected with either scramble or siAKT1 or siSHC at 28nM concentration 
by using lipofectamine RNAi for 72 hrs. siRNAs were purchased from dharmacon 
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siAKT1 (Cat#A-003000-18-0005) and siSHC (Cat#A-018841-16-0005). 
Lipofectamine RNAi was purchased from thermofisher scientific (Cat#13778030).  
 
Statistical Analysis 
The statistical analyses were conducted with R and GraphPad software packages 
(GraphPad). A Student t test or ANOVA test was used for comparison of 
quantitative data. The linear correlations between CALCR and miR-489 ligand 
expression in primary breast cancer tissues were evaluated with Pearson 
correlation coefficient analysis. The clinical effect of the gene expression profiles 
of miR-489 was further evaluated using two published datasets: Dvinge et al, 1302 
breast cancer patients (Dvinge et al., 2013), and Rinaldis et al, 181 breast cancer 
patients (de Rinaldis et al., 2013) .The patient samples were stratified into three 
equal groups based on the expression levels of miR-489. The two compared 
groups are the third of patients with the highest expression levels (high) versus the 
third of patients with the lowest expression (low) (H. Chen et al., 2008). Overall 
survival was estimated using the Kaplan-Meier method and compared with log-
rank tests. Univariate regression analysis and multivariate Cox PH regression 
analysis were performed to demonstrate the correlation between the patient 
survival and miR-489 while accounting for other potential predictors (covariates).  
The stepwise Akaike Information Criteria (AIC) method with “both” direction search 
was used with R step AIC function in the predictor variable selection during the 
multivariate regression.  The selected model was assessed with the overall 
Goodness-of-fit test.  Chi-square tests were made with the Schoenfeld residuals 
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to check the proportional hazard assumption of the selected model. Values of P < 
0.05 were considered significant. 
All data are shown as the mean ± standard deviation (SD); comparisons of 
two groups were analyzed using the two-tailed t-test with Welch’s correction using 
GraphPad Prism version 5.00 for Windows, (GraphPad Software, San Diego 
California USA, www.graphpad.com). P-values of p<0.05, p<0.01, and p<0.001 
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